e-TENDER NO:- BPPI/DRUG-065/2018

TENDER FOR SUPPLY OF DRUGS

TO

Bureau of Pharma Public Sector Undertakings of India (BPPI)

For the year 2018-2019

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

8th Floor, Videocon Tower, Block E1,
Jhandewalan Extension, New Delhi-110055
Telephone: 011- 49431811/49431824 /49431828/49431829/49431830;

Website: **janaushadhi.gov.in**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: 8th Floor, Videocon Tower, Block E1,Jhandewalan Extension, New Delhi-110055

Telephone: 011-49431811/49431824 /49431828/49431829/49431830;

Website: **janaushadhi.gov.in**

ONLINE TENDER FOR THE SUPPLY OF DRUGS TO BUREAU OF PHARMA PSU OF INDIA FOR THE YEAR 2018-2019

Tender Reference		**BPPI/DRUG-065/2018 Dt. 03/08/2018**
Date of availability of tender documents on website		**03/08/2018 (Friday)**
Doubts and queries regarding Tender document should be sent by e-mail to e-mail id "proc6@janaushadhi.gov.in, proc5@janausadhi.gov.in, proc7@janausadhi.gov.in" by the likely bidders latest by		**08/08/2018**
Time and date and place pre-bid meeting		**11:00 AM on** **10/08/2018 (Friday)** Bureau of Pharma **PSUs** of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Last date and time for submission of Online Bid i.e. Bid Submission End Date and time		**24/08/2018 up to 11.00 A.M.**
Last Date and time for submission of EMD and Original Annexure-II (Declaration) in physical Form in office of Bureau of Pharma PSUs of India, 8th Floor, Videocon Tower, Block-E1,Jhandewalan Extension, New Delhi-110055		**27/08/2018 up to 11:00 A.M.**

Time and date of opening of Technical Bid		**11:30 AM on 27/08/2018 (Monday)**
Place of opening of tender		Bureau of Pharma PSUs of India, 8th Floor, Videocon Tower, Block-E1,Jhandewalan Extension, New Delhi-110055
Address for Communication		Bureau of Pharma Public Sector Undertakings of India, 8th Floor, Videocon Tower, Block-E1,Jhandewalan Extension, New Delhi-110055
Cost of the Tender Document		**Free of cost**
Contact Person for clarification if any		1. Mr. P.K.Thakur, Executive (Procurement) Phone:- 011-49431858 Mob:- 9475982561 Email:- proc6@janaushadhi.gov.in
		2. Ms. Nisha Kumari, Executive (Procurement) Phone:- 011-49431858 Mob:- 9988290847 Email:- proc7@janaushadhi.gov.in
		3. Ms. Neha Aggarwal, Executive (Procurement) Phone:- 011-49431859 Mob:- 8447711358 Email:- proc5@janaushadhi.gov.in

The tender document can be downloaded free of cost from the CPPP e-Procurement Portal https://eprocure.gov.in and from *the website of BPPI:* ***janaushadhi.gov.in.***

TABLE OF CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

ONLINE TENDER FOR THE SUPPLY OF DRUGS TO BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

FOR THE YEAR 2018-2019

PRADHAN MANTRI BHARTRIYA JANAUSHADHI PARIYOJANA(PMBJP) is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called PRADHAN MANTRI BHARTRIYA JANAUSHADHI KENDRA (PMBJK). BPPI was established in December 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for PMBJP.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April 2010. BPPI follows the provisions of GFR 2017 as amended from time to time, the CVC guidelines, and instructions from the Department of Pharmaceuticals.

At present, more than 3800 stores are functional. It is proposed to channelize efforts to popularize PMBJP and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – C.E.O, Bureau of Pharma Public Sector Undertakings of India, 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055 (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India,(hereinafter referred as **BPPI** unless the context otherwise requires).

Tender Inviting Authority invites **Tender for the supply of Drugs to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, for the year 2018-2019.**

1. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDERS.

(a) Online Bids [in two separate Cover {Technical bid ("Cover A") and price bid (Cover "B")}] will be submitted till **11.00 A.M. up to 24/08/2018 (Friday) on** CPP portal i.e. eprocure.gov.in.

(b) The price bid shall be valid for a period of 120 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms &conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

2. ELIGIBILITY CRITERIA

(a) (i) Tenderer shall be a manufacturer having valid drug manufacturing unit duly licensed by licensing authorities. Loan licensee is also eligible.

(ii) Tenderer shall be direct importer holding valid import license. The manufacturer of foreign supplier should be WHO-GMP certified company. The Importer should have valid sale license.

(iii) **Distributors/Suppliers/Marketer/Agents are not eligible to participate in the Tenders.**

(c) (i) Manufacturer should have valid WHO-GMP (World Health Organisation-Good Manufacturing Practices) certificate issued by licensing authority.

(ii) A certificate from their C.A. (Chartered Accountant) or Company Secretary that

I. Average Annual turnover of manufacturer for manufacturing the drugs in the last three years i.e.2014-15, 2015-16 and 2016-17 shall not be less than **Rs.20 Crores.** In case of loan licensees average annual turnover of manufacturing unit/ Host Company in the last three years i.e. 2014-15, 2015-16 and 2016-17 shall not be less than **Rs.20 Crores.**

II. Manufacturer have manufactured & marketed at least 2 commercial batch of quoted drugs in last three years

OR

(**ONLY** i**n case of Importer**)

The supplier have marketed at least 2 commercial batch in last three years.

III. Manufacturer has Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period.

Or (**ONLY** i**n case of Importer**)

M/s _____ has Financial capacity to deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their marketing experience and financial statement.

IV. The bidder is required to have complete stability data (long term stability studies and accelerated stability studies) for all quoted drugs.

V. The manufacturer is required to declare the active API polymorphic form used in formulation for all quoted drugs and declare that it is internationally accepted active polymorph.

(c) Market Standing Certificate (MSC) issued by the state licensing authority under generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years.

(d) Non-conviction Certificate not older than 6 months issued by the licensing authority of the State certifying that the firm/company has not been convicted.

(e) Tenderer should not be submitted for the product(s) for which the firm / company has been blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies due to quality failure of the drugs ***at the time of submission of online bid.***

(f) The Tenderer should have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government / its Drug procurement agencies **at the time of submission of bid**. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/BPPI during last two years.

(g) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government / Central Government / its Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI along with relevant authentic document by the tenderer firm/ company within one month.

(h) The tenderer should confirm that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

(i) **Tenderer are required to incorporate bar codes as per GS1 standards at various packaging levels (primary, secondary and tertiary) (Annexure I) and they are required to submit valid registration certificate from GS1 India for such barcoding.**

3. GENERAL CONDITIONS.

(i) The tender document shall be download from the websites janaushadhi.gov.in; and CPP portal i.e.eprocure.gov.in. Tender Document is free of cost. No tender cost is to be deposited.

(ii) **EMD (Earnest Money Deposit)**: EMD of Rs.10,00,000/- (Rupees Ten Lakhs only as specified in Clause 7 of the Tender document in the form of **Bank Guarantee or Bankers Cheque or Demand Draft from nationalised/Scheduled Bank** favouring "Bureau of Pharma Public Sector Undertakings of India ", payable at Gurgaon/Delhi **which is to be delivered in original to BPPI, New Delhi on or before the date and time stipulated in bid document**. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMD instrument must be uploaded **(ANNEXURE III)** to the e-Procurement portal. EMD in any other form like ***cheque/cash/postal order*** etc. **will not be accepted. The Bid (in case not exempted for EMD as mentioned in tender document) without EMD shall be summarily rejected.**

(iii) Tenders will be opened online. However, authorized representatives of bidder who like to attend online bid opening on the specified date and time should bring letter of authority authorising to attend online bid opening on the printed letter head of the company. **Please also certify in authorisation letter that nominated person of tenderer shall not represent any other tenderer in BPPI.**

(iv) (a) At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by an amendment uploading on website on **janaushadhi.gov.in;** and CPP portal i.e. **eprocure.gov.in** will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

(b) Any person who has downloaded the tender document should watch for amendment, if any, on the website **janaushadhi.gov.in;** and CPP portal i.e.**eprocure.gov.in** for which BPPI will not issue any separate communication to them.

(v) Interested eligible Tenderers may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

(vi) During tender or price agreement period, if L1 bidder is debarred/deregistered/blacklisted/banned by any Central Government or state Government or its procurement agencies due to quality failure, BPPI may purchase the drugs from L2 bidder or may go for fresh tender as per discretion of BPPI.

(vii) The BPPI reserves the right to purchase any drugs full or part quantity from PSU as per discretion of BPPI. In case of emergencies, BPPI may go to PSU and price will be as per negotiation and at the discretion of BPPI.

3.1 SPECIAL CONDITIONS.

(i)Bids shall be submitted online only at CPPP website :https://eprocure.gov.in. Manual bids shall not be accepted except for the original documents/instruments as mentioned in tender document.

(ii) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e-Procurement Portal https://eprocure.gov.in.

(iii) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited and bidder is liable to be banned from doing business with BPPI.

(iv)Bidders are advised to check the *website of BPPI: janaushadhi.gov.in* and CPPP website https://eprocure.gov.in at least 3 days prior to closing date of submission of tender for any corrigendum, addendum, or amendment to the tender document.

4. TECHNICAL BID - COVER "A"

4.1. The Tenderer should upload the following documents in while submitting technical bid hereafter called **"Cover A". (Scanned copies of each page of all documents should be uploaded while submitting Technical bid).**

(a) The tenderers are required to upload scanned undertaking on stamp paper duly notarized by authorised signatory (**ANNEXURE – II)** confirming that they are holding the valid drug license, valid WHO- GMP certificate, 2 years market standing certificate for quoted products issued by licensing authority, a certificate for manufactured & marketed of two batches for quoted drugs within 3 years issued by CA or ICWA , valid Non conviction certificate not older than 6 months issued by licensing authority , valid import license, valid sale license (in case of Importer). undertaking as per para 2(f) & (h), undertaking to supply the drug with bar code as per ANNEXURE I and as per Annexure XI & XI A, undertaking for Clause 7.2, uploaded copy of complete stability data (long term stability studies and accelerated stability studies) for all quoted drugs, Upload declaration about the active API polymorphic form used in formulation for all quoted drugs along with documented evidence and declare that it is internationally accepted active polymorph, uploaded the copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document. In case the bidder is Importer, they may strike the clause or part of clause not applicable in their case. The drugs indicated in this undertaking shall only be considered for evaluation and opening of price bid. **On the basis of such undertaking, the price bid shall be opened within a week after opening of technical bid. However, the bidder is required to upload/submit all the documents along with the technical bid and in case any document is not complying as per undertaking, their contract/Price agreement shall be cancelled with forfeiture of EMD/Performance security deposit/Bank guarantee. The original ANNEXURE II should be submitted to BPPI, New Delhi before stipulated time and date**.

(b) Earnest Money Deposit as indicated in Clause 3(ii) and Clause 7. of the tender document shall be in the form of **Bank Guarantee or Bankers Cheque or Demand Draft** favouring "Bureau of Pharma Public Sector Undertakings of India "payable at Gurgaon/Delhi. Tender cost and EMD in any other form like ***cheque/cash/postal order*** etc. **will not be accepted.** Scanned soft copy of the EMD instrument must be

uploaded **(ANNEXURE III)** to the e-Procurement portal. and **original EMD instrument should be submitted to BPPI, New Delhi on or before the schedule date of technical bid opening.**

(c) The tenderers are required to upload a certificate from the C.A.(Chartered Accountant) or Company Secretary as per **ANNEXURE IV** certifying that (i) Constitution of bidding firm with details of PAN no., GST registration no., filed Income tax returned and GST retuned up to date and attested signature of authorised person,(ii) whether the bidder is Micro Small & Medium Enterprises (MSME) and owned/ not owned) by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs.(iii) Average Annual Turnover certificate of manufacturer/manufacturer of loan licensee (if applicable) in the last three years i.e.2014-15, 2015-16 and 2016-17 to manufacture the drugs, (iv) Manufacturer have manufactured & marketed at least 2 commercial batch in last three years or (in case of Importer)marketed at least 2 commercial batch in last three years (,(v) Manufacturer has Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period or Importer has Financial capacity to deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender.

(d) Authorization letter nominating an officer of the Tenderer on the printed letter head of the company to transact the business with the BPPI to be uploaded. **Please also certify in authorisation letter that nominated person of tenderer shall not represent any other tenderer in BPPI.**

(e) The Tenderer should upload Scanned copy of valid drug Manufacturing Licence for the product, duly approved by the Licensing Authority for each and every product quoted as per specification in the tender. The licence must have been duly renewed up to date and the items quoted shall be clearly highlighted in the licence. Original documents should be produced for verification when demanded. However, if renewal application for manufacturing licence has been filed, Scanned copy of same duly receipted by drug authorities must be uploaded along with the validity certificate from state licencing authority (SLA).

(f) Scanned copy of import license (in Form 10 with Form 41), as per Rule 122A of the Drugs and Cosmetics Act 1940, if the product is imported should be uploaded. The licence must have been renewed up to date. A copy of a valid licence for the sale of Drugs imported by the firms issued by the State Licensing Authority shall be uploaded. Original documents should be produced for verification when demanded.

(g) MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY UNDER generic or brand name as a Manufacturer for each product quoted in the tender for a minimum 2 years (Certificate should be uploaded with list of items)**.** In case of direct importer, evidence for importing the said items such as bill of landing, bill of entry and certificate of analysis as well as WHO-GMP certificate of manufacturing company are to be uploaded. MSC issued under brand name or under generic name (by the state licensing authority) will also be accepted but **supplies will be accepted as per packing and label by foreign manufacturer in their brand subject to affixing sticker for Logo as approved by BPPI & BPPI MRP.** However, for those newly launched drugs whose first product permission to manufacture and sale has been issued within 2 years by the respective country's / state drug authority, MARKET STANDING CERTIFICATE (MSC) issued by the respective country's /STATE LICENSING AUTHORITY under generic or brand name as a Manufacturer for less than 2 years shall be acceptable to BPPI. In

case the bidder is Importer, MARKET STANDING CERTIFICATE (MSC) ISSUED BY THE STATE LICENSING AUTHORITY shall not be applicable.

(h) **The copies of relevant pages approved by drug authorities of concerned country for any quoted Drug/product offering CoPP certificate and quoted drugs/ products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa should be uploaded with technical bid.**

(i) **Scanned** copy Non-Conviction Certificate issued by the licensing authority of the State certifying that the firm/company has not been convicted should be uploaded. **The certificate should not be more than 6 months old at the time of submission of technical bid**.

(j) **Scanned** copy of Valid WHO-GMP (World Health Organisation-Good Manufacturing Practices) Certificate (for manufacturer only) issued by the Licensing Authority should be uploaded. In case of Imported drugs, labels and product literature of all quoted product(s) must be uploaded COPP certificate as per WHO format of their Principal Manufacturing company/firm.

(k) Documents, if any, to show that the manufacturing unit/importer has been recognized by any other Indian / International Standard Organizations etc. as applicable. Importer should upload WHO-GMP certificate of manufacturer.

(l) The loan license bidder is required to upload scanned copies of all the documents as per tender requirements including manufacturing unit.

(m) (i) The tenderers are required to upload copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs.

(ii) The bidder shall upload the complete stability data (long term stability studies and accelerated stability studies) for all quoted drugs with technical bids. If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be uploaded along with licensing agreement. Otherwise, their bid is liable to be rejected.

(n) **The manufacturer shall declare the active API polymorphic form used in formulation for all quoted drugs and declare that it is internationally accepted active polymorph. The documented evidence shall be uploaded with technical bids. Otherwise, their bid is liable to be rejected.**

(o) **The bidders shall upload valid GS1 barcoding registration certificate and comply to barcoding requirement as per Annexure I of tender document.**

(p) A Checklist (**ANNEXURE- V**) shall be uploaded with technical bid. If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will uploaded as a

separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.

(q) All the documents uploaded should also be signed by the authorized official of the Tenderer.

4.2. The all documents indicated above should be uploaded and shall be opened at the time of Technical bid opening.

5. PRICE BID(BOQ) - COVER "B"

5.1. Cover "B" contains the Price Bid of the Tenderer.

(i) The Tenderer shall fill in the rate per unit size, % age rate of GST and total rate inclusive of GST in respective column of BOQ for the items quoted**. In case, any bidder offers CoPP or offers products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa, copies of relevant pages of valid document approved by drug authorities of concerned country for imported drug should be uploaded on line with technical bid.**

(ii)**Determination of L1 bidder:**

(a) In determining the lowest evaluated price, the rate quoted per unit size inclusive if GST as indicated in column No. 8 of the BOQ shall be taken into consideration.

(b) The Price preference of up to 5% over L1 bidder (if L1 bidder is not offering certificate of pharmaceutical product i.e. **CoPP** issued in the format recommended by the World Health Organization) shall be given to the bidder having CoPP for the particular drugs and shall be awarded contract. Scanned copy of Valid CoPP issued by the Licensing Authority must be uploaded.

(c) The Price preference up to 10% over L1 bidder (if L1 bidder is not offering products manufactured by manufacturing units approved by from US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa) shall be given to the bidder having product manufactured by manufacturing units approved by US FDA. TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa.

(d)(i) If the participating Micro and Small Enterprises (MSE) meets all the other eligibility criteria and their quoting price is within price band of L1+15 (fifteen) per cent shall also be allowed to supply a portion of requirement by bringing down their price to L1 price in a situation where L1 price is from someone other than a MSE and such MSE shall be allowed to supply up to 20 (twenty) per cent of total tendered value. The 20 (twenty) per cent quantity is to be distributed proportionately among these bidders, in case there are more than one MSMEs within such price band.

(ii) Within this 20% (Twenty Percent) quantity, a purchase preference of four per cent (that is, 20 (twenty) per cent out of 20 (twenty) per cent) will be reserved for MSEs owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs (if they participate in the tender process and match the L1 price). Provided that, in event of failure of such SC/ST MSE to participate in tender process or meet tender requirements and L1 price, four per cent sub-target shall be met from other MSE. MSEs would be

treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

Note 1:- (a) Price preference as in Clause 5.1 (ii) (c) will be get preference over the clause 5.1 (ii) (b).

Note 2:- Later on, if product does not comply CoPP and products manufactured by manufacturing units having approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa **as declared in tender, the extra price paid to the supplier shall be recovered in addition to other penal action.**

(iii) The rate quoted inclusive of GST in column 8 of **BOQ** should be for a unit size and for the given specification. **The rates quoted should be in rupees and paisa up to 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE-VII.**

(iv) GST (Goods and Services Tax)-The tenderers must indicate the rate of GST applicable and payable by them. In case no information is given, it shall be presumed that rate are inclusive of GST and no GST shall be charged by them under any circumstances.

(v) The bidder is required to indicate GST (%) in digit only in column 7 column of BOQ without suffixing % sign and not to indicate amount of GST in Rs. at particular cell of excel sheet of BOQ.

6. OPENING OF COVER "A" AND COVER "B" OF TENDER

6.1 Only authorized official as indicated in Clause 4.1. (d) are entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

6.2 Tenderers, who are found eligible on satisfying the criteria for technical evaluation/based on undertakings & Declaration, will only be informed the time and date of opening of Price Bid - Cover "B" of the tender.

6.3 In case, the date for opening of technical bid is declared holiday, the technical bid shall be opened on next working day at 11.30 A.M.

7. EARNEST MONEY DEPOSIT

7.1. The Earnest Money Deposit referred to under Clause 3(ii) & 4.1(a), shall be **Rs. 10 lakhs. The Earnest Money Deposit shall be paid in the form of Bank Guarantee or Bankers Cheque or Demand Draft in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Gurgaon/Delhi. In case EMD in form of Bank Guarantee, Irrevocable Bank Guarantee** in favour of Bureau of Pharma Public Sector Undertakings of India from any Nationalised/scheduled Bank should be valid

for a period beyond **270 days/9 months from the date of tender opening**. The format of Bank Guarantee is at **ANNEXURE-VI.** BPPI will not pay interest on any deposit held in the form of **Bankers Cheque or Demand Draft.**

7.2. (i) The tender submitted without sufficient EMD will be summarily rejected.

(ii) The Earnest Money Deposit will be refunded to the successful bidders within 30 days from the date of acceptance of rate for price agreement and on the deposit of Performance security deposit.

(iii) The Earnest Money Deposit (EMD) of the unsuccessful bidders will be returned after finalization of tender with eligible bidder.

(iv) The Earnest Money Deposit (EMD) will be forfeited, if the tenderer withdraws his bid any time after opening of price bid / non submission of Performance security within the period prescribed/non supply of drugs.

(v) The Earnest Money Deposit (EMD) will be forfeited, in case of the lowest bidder, fails to execute the contract or deposit the performance security deposit within the stipulated time**.** The EMD shall be forfeited if the undertaking as Annexure III is not found correct.

(vi) Tenderer may be exempted from the payment of EMD, if valid **registration** certificate from NSIC/MSME is uploaded **for the product for which bidder has submitted quotation.**
(vii) PSUs are exempted from the payment of EMD.

8. OTHER CONDITIONS

8.1.(i) The details of the required drugs, medicines, etc., are shown in **ANNEXURE -VII**. ***The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** by the BPPI, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the price agreement, the BPPI, will confirm the actual requirement then / there through purchase order/orders. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

(ii) The Tenderer shall fill in manufacturing capacity per year in units, Shelf life in months and manufacturing batch size in units for each quoted drugs in required column of **ANNEXURE – VIII and upload along with technical bid.** In case the bidder is Importer, the importer is required to sign and upload ANNEXURE VIII on behalf of the exporter which would be supported by documentary evidence provided by the manufacturer.

(iii) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the acceptance of tender for price agreement.

(iv) The rates quoted shall not be varied with the ordered quantity during the full contract period.

8.2. Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product

should be as per specifications given in **ANNEXURE-VII**. Any variation, if found, will result in rejection of the tender. However, the imported/combination drugs are allowed to quote in trade / brand name.

8.3. Rates (inclusive of Customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, but exclusive **GST** should be quoted for each of the required drugs, medicines etc., separately on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

8.4. Each bid must contain not only the unit rate but also the total value of each item quoted for supply in the respective columns. The aggregate value of all the items quoted in the tender shall also be furnished.

8.5. (i) The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer. Tender Inviting Authority at its discretion, may exercise, the right to revise the price at any stage so as to conform to the controlled price or MRP or the selling price of the tenderer as the case may be. This discretion will be exercised without prejudice to any other action that may be taken against the Tenderer. In case delivery of drugs is not made within delivery period mentioned in Purchase order, the supplier must confirm from BPPI whether BPPI MRP is to be reduced due to changes in DPCO ceiling rate after issue of purchase order.

(ii) **FALL CLAUSE:**

If at any time during the execution of the contract, the controlled price becomes lower or the supplier reduces the sale price or sells or offers to sell such stores, as are covered under the contract, to any person / organization including the purchaser or any department of Central government/state Govt. or its procurement agencies at a price lower than the price chargeable under the contract, he shall forthwith notify such reduction or sale or offer of sale to the purchaser and the price payable under the contract for the stores supplied after the date of coming into force of such reduction or sale or offer of sale shall stand correspondingly reduced.

8.6. The rates quoted and accepted will be binding on the Tenderer for the full contract period of one year and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. **However, Price agreement validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.**

8.7. No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS

AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

8.8. Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

8.9. The Tenderer shall allow inspection of the factory at any time after the opening of technical bid and during the entire contract period by a team of Experts/Officials nominated by the Tender Inviting Authority for the purpose. The Tenderer shall extend necessary cooperation to such team in inspection of the manufacturing process, quality control measures adopted etc., in the manufacture of the items quoted. If Company/Firm does not allow for any such inspection, their tenders will be rejected. If any such situation arises after placement of contract, the same shall be cancelled at the firm's risk cost.

8.10 "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

9. ACCEPTANCE OF TENDER

9.1. (i**)** Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done based on rate per unit size inclusive of GST as mentioned in **column 8** of **BOQ considering price preference for CoPP and for products manufactured by manufacturing units having approval of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa**.** However, to have additional source of supply, the L1 bidder shall be awarded contract/Price agreement for 60% of tender quantity indicated in the tender document. Balance 40% of the tender quantity indicated in the tender document shall be awarded to **L2 bidder if they agree to supply the drugs at L1 rates.**

(ii) In case, L2 bidder does not agree to match L1 rate, 100% tender quantity shall be awarded to L1 bidder. The purchase order shall be issued to L1 bidder and L2 bidders simultaneously as per discretion of BPPI depending upon requirement. In case, order is placed only on L1 bidder and if they fail to supply in stipulated time or due to quality failure, the purchase order shall be issued to L2 bidder. During the Price agreement period of one year, in case L1 bidder completes the supply of drugs for contracted quantity if no simultaneously purchase order issued to L2 bidder, next supply shall be taken from L2 bidder accordingly for contracted quantity.

(iii). The issue of purchase orders in same manner as mentioned above. Negotiation if required will be done at our premises and the same will be done strictly as per Central Vigilance Commission guidelines.

Note 1.:- No quantity distribution shall be applicable if L1 rates quoted by more than one bidder keeping in view of sharing of quantity as per clause no. 11(c) provided that no L1 bidder has CoPP certificate or drug/ Products manufactured by manufacturing units having approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa.

.**Note** 2. In case, MSME bidder is not eligible as per clause 5.1(ii)(d) and single bid is available after determination of L1 bidder **considering price preference 5% for CoPP and 10% for products manufactured by manufacturing units having approval of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa**, Such bidder shall be awarded 70% of quantity indicated in tender document and balance 30% quantity shall be awarded to lowest bidder at their quoted rates if applicable or L2 bidder at lower rate by 5% over L1 rate in case of CoPP bidder and by 10% over L1 rate in case product having approval of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa **approved product.**

Note 3. No undue advantage shall be given for additional quantity to L2 Bidders or MSME while matching/reducing the rate with respect to L1 rate.

9.2. BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

9.3. BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections.

9.4. BPPI also reserves right to place one-time purchase order for certain quantity for any drug without price agreement for one year for such drugs and suppliers are required to pay performance security deposit @ 5 % of value of order of such drug in form DD or Performance Bank Guarantee.

9.5. The acceptance of the tenders for Price Agreement for one year period will be communicated to the Tenderers in writing **(ANNEXURE IX).**

10.PERFORMANCE SECURITY DEPOSIT

10.1 Performance security deposit:

On being informed about the acceptance of the tender for 1 year price agreement, the Tenderer shall pay the Security Deposit @5% of **value of quantity of price agreement in** the form of ***Demand Draft or irrevocable Bank Guarantee*** in favour of Bureau of Pharma Public Sector Undertakings of India from any scheduled Bank. In case the Security Deposit is paid in form of Bank Guarantee, the bank guarantee shall be valid for a period beyond **one year of the validity of the price agreement**. The format of Performance Bank Guarantee is at **ANNEXURE-X.** Due to non- purchase of quantity mentioned in the acceptance letter for 1year price agreement at later stage, tenderer shall be allowed to replace bank Guarantee with lesser amount fresh Bank Guarantee if tenderer requests for such replacement.

10.2. The Tenderer shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons what so ever.

10.3. All notices or communications relating to and arising out of this price agreement or any of the terms thereof shall be considered duly served on or given to the Tenderer if delivered to him or left at the premises, places of business or abode as provided by the tenderer.

10.4. If the lowest selected Tenderer fails to deposit the required performance security deposit within the time specified or withdraws the tender, after the intimation of the acceptance of the tender or owing to any other reasons to undertake the contract, the contract will be cancelled and the Earnest Money Deposit deposited by the tenderer along with the tender shall stand forfeited by the BPPI and the firm will also be liable for all damages sustained by the BPPI apart from blacklisting and other penal actions. The performance security deposit shall be forfeited if the undertaking as Annexure II is not found correct.

10.5. The performance security deposit of supplier will be returned by BPPI only after the supplier has given undertaking on stamp paper (duly notarized) to replace such medicines and indemnify BPPI against any loses on account of quality parameters.

11.METHODOLOGY FOR PLACING ORDERS

For the above purpose the following procedures will be adopted

(a) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed**.**

(b) The Successful Tenderer is eligible for the placement of Purchase Orders only after depositing the required amount as Performance Security.

(c) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers are eligible for price agreement and the placement of Purchase Orders for such item(s) for which they are declared as lowest. Placement of order shall be shared equally amongst these bidders subject to their manufacturing capacity.

(d) In the case of purchase of goods where the quantity offered at the lowest price is less than the total quantity required, the BPPI may, after placing orders with the lowest evaluated Tenderer for the entire quantity offered by such Tenderer subject to his ability to supply, require all the other eligible Tenderers who participated in the tender and offered a price higher than that offered by the lowest evaluated Tenderer, to submit sealed offers of the quantity they would be willing to supply at the price quoted by the lowest evaluated Tenderer, and thereafter place orders for the remaining required quantity with all those who match the lowest evaluated price such that those who bid lower prices in the original tender get a higher priority for supply.

(e) If a supplier fails to execute supply order, the 5% value of supply order shall be recovered from pending bill or EMD/Bank Guarantee and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI.

(f) Notwithstanding anything contained in para (e) above, the supplier, after committing the default in supply either partly or fully, can inform the BPPI about his willingness to execute the Purchase Order during the tender period. The BPPI at discretion may consider the willingness of the supplier on merit. However, such supplies will be subjected to the levy of Liquidated Damages, unexecuted fine and other penalties as stipulated in the tender document, price agreement and purchase order.

(g) The supplier shall start supply of the Drugs/Medicines required by BPPI at Central Ware House (CWH), Gurgaon or any other place decided by BPPI within the stipulated period.

(h) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

(i) The supplier shall supply the Drugs/Medicines at the CWH, Gurgaon (or any other place decided by BPPI) along with copy of Purchase order, copy of test reports and 3 original copies of Invoice, original label and aluminium sheet (if applicable) sample of primary label. No payment will be processed without test reports.

(j) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also the supplier shall ensure the quantity relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice. Drugs to be supplied of any batch shall not be accepted with different MRP.

(k) It is the duty of the supplier to supply Drugs/Medicines at the CWH Gurgaon or any other place decided by BPPI and supply shall conform to the conditions mentioned in the provisions of tender documents, viz., logo, nomenclature, specification etc.,

(l) Subject to above, BPPI will process the invoices submitted by the supplier and the payments against supply will be made within 60 days from the date the Drugs/Medicines supplied has been declared of STANDARD QUALITY, by the Empanelled laboratory of BPPI subject to various terms and conditions of the tender.

(m) Subject to the conditions mentioned in the Purchase Order, Tender Document, Price Agreement and here under, the Supplier is entitled for the payment against supply. In case of any discrepancy in levy of LD, Penalty, Unexecuted Fine, Short Passing of Bills, such discrepancy shall be intimated within 30 days from the date of receipt of payment, failing which BPPI will not entertain any claim thereafter.

(n) BPPI reserves the right to place upto 50% additional purchase order of the quantities as contracted within validity of contract.

12. SUPPLY CONDITIONS

12.1. Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at the central warehouse at Gurgaon or any other place decided by BPPI.

12.2. Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through fax and mail the confirmation for the receipt of the purchase order.

12.3. The Tenderer should also fax and mail the details of supply dates as specified in Annexure, to BPPI within 7 days from the receipt of the purchase order. In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and BPPI shall purchase the drugs from alternative sources.

12.4. (a) For the first purchase order, the supplier must supply the ordered quantity within 45 days from the date of Purchase Order. For drug code 574, Rabies Vaccine Inj. 2.5 IU, period shall be 90 days instead of 45 days.

(b) For Subsequent purchase orders, the supplier shall complete the supply within 30 days from the date of purchase order at the destinations mentioned in the purchase order. However, for Injectables/ infusion / vials the delivery period shall be 45 days instead of 30 days. For drug code 574, Rabies Vaccine Inj. 2.5 IU, period shall be 90 days instead of 30 days.

(c) If the above day for 12.4 (a) &(b) above happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

(d) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

(e) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 18.

((f) The liquidated damages as specified in clause 18.1 and 18.2 of the tender conditions will be levied on the quantity supplied after the 45thday and 30th days/45days for Injectables/ infusion / vials (90th days for code 574, Rabies Vaccine Inj. 2.5 IU) for 12.4 (a) & (b) respectively. However, no supplies will be accepted after 75th days and 60th days/75th days for

Injectables/ infusion / vials (120th days for drug code 574, Rabies Vaccine Inj. 2.5 IU) for 12.4 (a) &(b) respectively from the date of issue of purchase order and the purchase order shall be cancelled at the risk and cost of the supplier. **However, the supplier must take prior approval from BPPI for supply of drugs beyond stipulated delivery period in Purchase order.**

12.5. Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders. **Further, supplies against a purchase order are to be made in minimum numbers of batches as far as possible and same batch should not be supplied in repeated consignment.**

12.6. The supplied Drugs (covered in SCHEDULE "P" of Drugs and Cosmetics Act) should have the prescribed potency throughout the shelf life period as prescribed in the Drugs and Cosmetics Act 1940 and rules there under and in relevant Pharmacopoeias. **However, in case of thermolabile drugs not covered in SCHEDULE "P" of Drugs and Cosmetics Act, the minimum shelf life should be 2 years from the date of manufacture.**

12.7. The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with IP/BP/USP and the specifications, stipulations and conditions specified in the tender.

12.8. Tenderer should supply the product **(a) within 2 months excluding month of manufacture of products having shelf life up to 2 years, (b) within 3 months excluding month of manufacture of products having shelf life more than 2 years & up to 3 years and (c) within 4 months excluding month of manufacture of products having shelf life more than 3 years (d) Within 3.5 months excluding month of manufacture of products for drug code 574, Rabies Vaccine Inj. 2.5 IU.** Products beyond the above-mentioned period from the date of manufacture shall not be accepted. For example, product having manufacturing of November 2018 must be supplied by 31st January, 2019 in case shelf life less than 2 Years.

For imported products, 60% of shelf life should be available at time of supply.

12.9. If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to Force Majeure events such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The exceptional events does not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

12.10. The supplier shall not be liable to pay LD and forfeiture of performance security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

12.11. **Suppliers are required to supply the drugs within the delivery period mentioned in the purchase order. In this regard it is informed to the bidders that their performance shall be considered unsatisfactory in case of delayed supply (beyond delivery period) or non-supply of products. BPPI may reject their bid in future tenders considering their unsatisfactory performance of supplies.**

12.12 If BPPI observes some physical defects(like empty blisters, improper labelling) of the supplies during sampling, the batch shall be rejected. If supplier wants to take back the batch for rectification, they can take back at their cost, rectify and send back to BPPI within 10 days otherwise same batch shall not be accepted. Due to rectification, if its shelf life condition as per tender provision does not meet, it shall be discretion of BPPI depending upon requirement to accept the goods with penalty.

13. LOGOGRAMS

Logogram means, wherever the context occurs, the design as specified in **ANNEXURE-XI. The name of the drug shall be mentioned in English and Hindi** as per pharmacopoeia and its strength.

13.1. Tenders for the supply for Drugs etc., shall be considered only if the Tenderer gives an undertaking that the product(s) will be prepared as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **ANNEXURE –XI** &**XI-A**.

13.2. All dosage form have to be supplied in packing as specified in product list (**ANNEXURE VII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

13.3. Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed PMBJP logogram of proportionate size.

13.4. Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of price agreement / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier.

Tenderers who are not willing to agree to conditions above will be summarily rejected.

13.5. For imported Drugs, the supplies will be accepted as per packing and label by foreign manufacturer in their brand subject to affixing sticker for Logo as approved by BPPI & BPPI MRP.

14. PACKING

14.1. The drugs shall be supplied in the package specified in **ANNEXURE - VII** and **ANNEXURE -XII** and the package shall carry the logograms of proportionate size specified in **ANNEXURE –XI, XI -A**. Non affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 18.5

14.2. The minimum size of each tablet should be 6.4 mm in diameter and the minimum size of the blister packing/strip packing/Alu-alu packing should be 80mm x 35mm/50mm x 130 mm/45mm x 110mm respectively. The drugs in any dosage form to be supplied by the supplier should not be embossed indicating any code no./logo or name of the company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.3.

14.3. The packing in each carton shall be strictly as per the specification mentioned in **Annexure-XII**. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**). **The material to be used for carton should be from virgin chemical pulp.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 18.5. Storage conditions must be indicated on outer label.

14.4. The cap of bottle preparations should not carry the name of the supplier.

14.5. The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intra Muscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

14.6. It should be ensured that only first-hand virgin packaging material of uniform size, including bottle and vial, is used for packing.

14.7. All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

14.8. Packing should be able to prevent damage or deterioration during transit.

14.9. In the event of items of drug supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 18 & 19.

14.10. Designs of packaging with the logograms shall be subject to approval by BPPI within 3 days of receipt of purchase order. Text matter of all type of label must be checked and responsibility shall be of manufacturer. In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in **ANNEXURE XI and XIA. T**he specifications for all quoted drugs and STP (Standard Testing Procedure) for Non- Pharmacopoeia drugs in form of soft copy are to be uploaded with technical bid.

14.11. The colour of the strength must be different from the colour of the generic name of the drug on primary and secondary packaging and the approval for the same should be taken from the quality/regulatory department while taking artwork approval. The printing ink used should be of good quality (clarity, brightness, contrast) which is easily readable.

14.12. WHO-GMP certified, Therapeutic code & NABL lab tested shall be indicated on the primary and secondary packaging and shall be incorporated as per the approval from the quality/regulatory department while taking artwork approval.

15. QUALITY TESTING

15.1. Samples of supplies from each batch will be chosen at the point of dispatch at supplier's site or receipt of supply or distribution/storage points for testing at discretion of BPPI. The samples will be sent to different laboratories including Government Drugs Testing Laboratory/NIPER/PSU labs for testing as decided by the BPPI. Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 17.

15.1.1 Supplier should send the soft copy of the specifications for all approved drugs and STP (Standard Testing Procedure) for Non- Pharmacopoeia approved drugs by mail to Quality and Regulatory officer of BPPI with art work approval for design of packaging with the logogram as per Clause 14.10; if they failed to upload/submit the same with technical bid.

15.2. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also action will be initiated for blacklisting as per clause No.19 irrespective of the period of supply. The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

15.3. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 19.

15.4. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded.

15.5. The products should conform to the standards of IP/BP/USP/EP/JP as the case may be. **However, the drugs notified in the IP (amended up to date) shall be accepted only if supplied conforming to the standards outlined in the IP.** In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing. For imported drugs, respective Country's Pharmacopoeia standards shall be acceptable (even if the product is official in IP).

15.6. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 19. If such lapses happen more than twice in a tender period such cases will be treated as "Misbranded Drugs".

16. PAYMENT PROVISIONS

16.1. No advance payments towards costs of drugs, medicines etc., will be made to the Tenderer.

16.2. Payments towards the supply of drugs will be made within 60 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original **(ANNEXURE - XIII)** to make the payment through RTGS/Core Banking/NEFT.

16.3. All bills/Invoices should be raised in triplicate and the bills should be drawn as per GST Rules in the name of Bureau of Pharma Public Sector Undertakings of India. 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055or in the name of any other authority as may be designated.

16.4. (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI.

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

(a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within delivery period stipulated in purchase order from the issue of such purchase order.

(b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 60 days from the date of last supply.

(c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

16.5. If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself,

the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

16.6. In case of any increase of decrease in the taxes/GST after the date of submission of tenders and during the tender period, such variation in the taxes/GST will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes/GST, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned authorities and also must claim the same in the invoice separately. However, the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly, if there is any reduction in the taxes/GST and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the basis of the reduced taxes/GST/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender. Any increase or decrease in taxes/GST and statutory levies will be considered based on the notification issued by the Government.

However, if the firm supplies after originally stipulated Delivery period, increase in taxes/GST due to statutory variation in taxes/GST shall be borne by the supplier. In case of decrease in taxes/GST due to statutory variation in taxes/GST, the same shall be passed on by the supplier to the BPPI.

17. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

18. LIQUIDATED DAMAGES AND OTHER PENALTIES:

18.1. If the supply reaches the designated places or Central Warehouse after 5 PM of **45th day** from the date of issue of the Ist purchase order and after 5 PM of the **30th day/45th day** for Injectables/ infusion / vials from the date of issue of the subsequent purchase order (90th days for drug code 574, Rabies Vaccine Inj. 2.5 IU), a liquidated damages will be levied at 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply. If the 45th/30th day (90th days for drug code 574, Rabies Vaccine Inj. 2.5 IU) happens to be a holiday the supply will be accepted on the next working day without any penalty.

18.2. If the supply is received in damaged condition, open delivery of the supplies shall be received, wherein it is possible to physically inspect the shipment. Damaged products shall not be accepted.

18.3. All the Tenderers are required to supply the product(s) with printed MRP as per purchase order and logogram of appropriate size on the strips, blisters, vials, ampoules& bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product and/or a separate damages will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually

suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.14.11 and 13.4.

19. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

19.1. If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the BPPI Such stock shall be taken back at the expense of the Tenderer. Further, actual handling and testing charges shall be paid to BPPI by the supplier otherwise these charges shall be recovered from their pending bill/EMD/performance security deposit. The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice, and shall also collect demurrage charges calculated at the rate of 2% per week on the value of the drugs rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

19.2. If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description(Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

19.3. For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to BPPI, BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company. If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs for a period of 5 years from the date of blacklisting. In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs for a period of 2 years from the date of blacklisting. In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Performance security deposit will also be forfeited.

19.4. The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

19.5. The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at

liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Performance security deposit.

19.6. For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Performance security deposit.

19.7. Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years besides forfeiture of Performance security deposit.

19.8. In the event of making Alternative Purchase, as specified in Clause 12.4 (a), Clause 14.11 and in Clause 15.3 penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance security deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

19.9. In all the above conditions, the decision of the BPPI shall be final and binding.

20. BLACK LISTING IN THE EVENT OF WITHDRAWL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE

20.1. BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

(a) If the Tenderer(s) fails to perform the obligations under the tender conditions / commits default in the performance of the contract, such Tenderers will be blacklisted for a period of 2 years by BPPI from the date of observing the defect besides forfeiture of Performance security deposit.

BLACKLISTING FOR QUALITY FAILURE

20.2.1. Quality Test by the Empanelled Laboratories of BPPI

a. Each batch of drugs/medicines shall be subjected to quality test by the Empanelled laboratories.

b. The samples collected from each batch of supply of the each drugs will be sent to the empanelled testing laboratories for testing the quality of drugs. In addition to the above BPPI shall also draw the samples of products supplied in the market place and get the same tested, to make sure the products are conforming to quality requirements.

c. If sample passes quality test in all respects, BPPI will instruct its Warehouse to release such items of drugs.

d. If the sample of any batch fails in quality test and report is received stating " Not of standard quality " in any test the report along with the chromatograms etc. such batch of drugs shall be rejected & no further procurement of that drug from the supplier will be taken for two years from the date of sample being declared not of standard quality.

(i) If the supplier challenges and request for retesting, the sample shall be tested at government testing laboratory or reputed govt. institute like NIPER. The test report of govt. lab or NIPER will be final and will be binding to the supplier.

(ii) The cost of such retesting shall be recovered from the supplier.

(iii) If **2** batches of item/drug supplied by the same supplier is reported to NOT OF STANDARD QUALITY in specification, then the firm shall be blacklisted for 2 years after observing procedure laid down in Para 20.2.3 besides forfeiture of Performance security deposit.

(iv) The supplier shall give a report of root cause and CAPA taken to prevent the recurrences of such failure within 20 days.

20.2.2 Quality Test by Statutory Authorities:

(a) If any drug is declared "NOT OF STANDARD QUALITY", by any government agencies or drug licensing authority, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/JAS will be retrieved.

(b) If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period or during quality check within shelf life period, the company/firm shall be blacklisted for a period of 2 **years from the date of blacklisting** after observing procedure laid down in Para 20.2.3.

20.2.3 Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/MISBRANDED" (**As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Performance security deposit

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for that particular item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

20.3 BLACKLISTING FOR NON-SUPPLY:

Due to non supply of item against any purchase order, 5 % value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase. In case of repeated circumstances of non supply of items i.e. 2 times , the supplier may be blacklisted for 2 years in addition of forfeiture of performance security deposit/ EMD and other penal action.

21. SAVING CLAUSE

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

22. RESOLUTION OF DISPUTES

(i) The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract.

ARBITRATION AND JURISDICTION

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/price agreement.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/price agreement leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the President/ CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

23. APPEAL:

(i) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India within ten days from the date of receipt of order and the Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India shall dispose the appeal within fifteen days from the date of receipt of such appeal.

(ii) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

24. CONTACTING THE BPPI BY THE BIDDER:

(i) No bidder shall contact the *BPPI* on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.
(ii) Any effort by a bidder to influence the *BPPI* in the *Purchaser*'s bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.
(ii) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.
(iv) Not withstanding anything contained in clause (iii) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

25. FRAUDULENT AND CORRUPT PRACTICES:

(1)For bidders:
It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (*In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper)* In pursuance of this policy, the purchaser;
(a) defines, for the purposes of this provision, the terms set forth below as follows:
(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party (*"another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.*

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (*a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution).*
(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party [*"parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non competitive level]*.

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (*a "party" refers to a participant in the procurement process or contract execution).*

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its

knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

(b) will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

(c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub contractors engaged in corrupt, fraudulent, collusive, or coercive practices.

(d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

(e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

(2) For suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Performance security deposit apart from other penal actions.

(a) For the purposes of this Sub-Clause:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) "obstructive practice" is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

26. JURISDICTION

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

ANNEXURE I

(BARCODE REQUIREMENTS}

Reference clause 2(i)

GS1 barcode requirements on Drugs procured by Bureau of Pharma Public Sector undertakings of India (BPPI)

These requirements cover medicines/drugs procured by Bureau of Pharma Public Sector Undertakings of India (BPPI), New Delhi meant for supply and distribution through BPPI regulated distribution channel.

Barcode based on GS1 identification standards are provided below at various levels of product packaging which includes primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to BPPI.

GS1 India is unique identification & barcoding standards body setup by Ministry of Commerce & Industry, Govt. of India along with APEDA, BIS, Spices board, IIP and apex industry chambers like CII, FICCI, ASSOCHAM to assist India industry and govt. bodies on adoption of global standards.

Suppliers are also required to provide GS1 subscription validity certificate at the time of supply of medicines/drugs issued by GS1 India. For validity certificate suppliers can contact GS1 India at 011-4289-0890

Barcodes based on GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

Technical Specification for GS1 Standards

Tertiary Level Pack: Data attributes captured

a) *Unique product identification code (GTIN - Global Trade Identification Number)*
b) *Expiry date*
c) *Batch no.*
d) *Quantity*
e) *Serial Shipping Container Code (SSCC)*

e.g. *1st Barcode: (02)1 8901072 00253 4 (17) 180815 (10) RNBXY0514 (37)5000*
2nd Barcode :(00) 1 8901072 001234567 6

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the*	*2*	*Fixed*	*Numeric*

	barcode			
1 8901072 00253 6	*Unique Product Number-GTIN-14*	*14*	*Fixed*	*Numeric*
(17)	*Application Identifier to indicate Expiry date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
180815	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*
(10)	*Application identifier to indicate Lot/batch number* *Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
RNBXY0514	*Batch No / Lot No*	*20*	*Variable*	*Alphanumeric*
(37)	*Application identifier to indicate Quantity in Outer Carton*	*2*	*Fixed*	*Numeric*
5000	*Quantity/no of units*	*Upto 8*	*Variable*	*Numeric*
(00)	*Application identifier to indicate the SSCC Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 001234567 6	*Unique number of the tertiary pack*	*18*	*Fixed*	*Numeric*
Recommended Barcode – GS-128				



Secondary Level Pack: Data Attributes Captured

a. *Unique product identification code (GTIN)*
b. *Expiry date*
c. *Batch No.*
d. *Qty*

e.g. Barcode - *(02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 500*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 00253 6	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(17)	*Application Identifier to*	*2*	*Fixed*	*Numeric*

	indicate Expiry date *Brackets not encoded in the barcode*			
180815	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*
(10)	*Application identifier to indicate Lot/batch* *Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
RNBXY0514	*Batch No / Lot No*	*Upto 20*	*Variable*	*Alphanumeric*
(37)	*Application Identifier to indicate serial number* *Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
500	*Quantity/Units in Secondary pack*	*Upto 8*	*Variable*	*Alphanumeric*
Recommended Barcode depending upon the space available – GS1 Data matrix *Or* *GS1-128*	 (02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 500 *or*  (02) 1 8901072 00253 6 (17) 180815 (10) RNBXY0514 (37) 500			

Primary Level Pack: Data Attributes Captured

a. Unique product identification code (GTIN) ***Barcode e.g. -*** *(01) 1 8901072 00253 6*				
Attribute	**Description**	**Length**	**Nature**	**Data Type**
(01)	*Application Identifier to indicate GTIN-14* *Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 00253 6	*GTIN-14 with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
Recommended Barcode – GS1 Datamatrix,	 (01) 1 8901072 00253 6			

Please contact GS1 India office for any further assistance –

GS1 India
(Under Min. of Commerce, Govt. of India)
330, 2nd Floor, 'C' Wing, August Kranti Bhawan,
Bhikaji Cama Place, New Delhi - 110066
T +91-11-42890890, (D) +91-11-42890846
F +91-11-26168730
E ankit@gs1india.org
W http://www.gs1india.org

ANNEXURE –II

(On nonjudicial Stamp Paper)

Ref. Clause No. 4.1(a)

DECLARATION

I/We M/s. …… represented by its Proprietor/Managing Partner /Managing Director having its registered office at …….....and its factory premises at ……
……do hereby declare as under:-

(I) that I/we have carefully read all the terms and conditions of tender in ref. no**. BPPI/DRUG-065/2018 dated 03/08/2018** including Amendment(s) to Tender document (if any) issued by Bureau of pharma public sector undertakings of INDIA, New Delhi,122016 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

(II) that I/We are holding and have uploaded (a) valid drug license for quoted drugs,(b) valid WHO-GMP certificate , (c) 2 years market standing certificate for quoted products issued by licensing authority, (d) a certificate manufactured & marketed two batches within 3 years issued by C.A. for quoted drugs, (e) valid non conviction certificate not older than 6 months,(f) Valid Import license (If applicable),(g) copy of complete stability data (long term stability studies and accelerated stability studies) for all quoted drugs. If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be uploaded alongwith licensing agreement,(h) declaration of the active API polymorphic form used in formulation for all quoted drugs along with documented evidence and declare that it is internationally accepted active polymorph. and (i) **t**he copies **of** the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document. . On the basis of such undertaking, the price bid shall be opened within a week after opening of technical bid. However, any document uploaded with technical bid is not complying as per undertaking, the contract/ Rate Contract shall be cancelled with forfeiture of EMD/Performance Security Deposit/Bank guarantee against tender no. BPPI/DRUG-065/2018 dated 03/08/2018 along with other action**.**

(III) a.) I/We declare that we possess the valid drug manufacturing licence for BPPI's tendered items as per details below:

Sr. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Drug Lic. No.	Date of Issue	Validity of Drug Lic.	Address of Manufacturing Unit

b.) I/We declare that we possess the valid WHO-GMP(World Health Organisation-Good Manufacturing Practices) Certificate issued by competent authority and complies and continue

to comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest Money Deposit and /or Performance security deposit and blacklist me/us for a period of 5 years if, any information furnished by us proved to be false at time the of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

(IV) (a) I do hereby declare that I have uploaded valid GS1 registration certificate for bar coding and will supply the drug with bar code as per ANNEXURE I and as per the design as per enclosures to ANNEXURE XI enclosed with tender document as well as other instruction given in this regard.

(b) Further, I / we do hereby declare that I will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to Annexure XII A as well as other instructions given in this regard.

(c) We have valid COPP certificate as per WHO format and approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, (if any) only for following quoted drugs and relevant certificate & approval indicating/highlighting drug code have been uploaded with technical bid:-

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Whether Valid COPP certificate (Yes/ No)	If Yes, then indicate the validity date of COPP Certificate	Whether approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa (yes/No)

(V) that in pursuant to the conditions in Clause No. 7.2 of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

(VI) that our company/applied items have not been blacklisted/debarred/de-registered/banned due to quality failure of the drugs supplied either by any State government or Central Government Organization or its drug procurement agencies for the following products quoted in the tender at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement

agencies/BPPI during last two years. We are eligible to participate in the tender ref. No. **BPPI/DRUG-065/2018 dated 03/08/2018** for the following quoted products:-

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size

Signed.....

Name

Designation

(Company Seal)

Witness:-(1).....

(2).....

To be attested by the Notary

ANNEXURE-III

Ref. Clause No. 3(ii , 4.1(b) & 7.1

DETAILS OF E.M.D SUBMITTED

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER/BANK GURANTEE

ANNEXURE- IV

Ref. Clause No. 4.1(b)

{Format for a certificate from the C.A.(Chartered Accountant) or Company Secretary}

(I) It is certified that M/s. ..... …… is a Private Ltd./Ltd./Proprietorship/Partnership company/firm and they have PAN no……..and GST registration no. ……..They have filed Income tax returned and GST returned up to date. The authorised signatory of the company/firm is Shri …….and whose signature is attested as under:----------

(II) The annual Turnover of M/s. .....for manufacturing the drugs in past three years are given below and certified that the statement is true and correct.

Sl.No.	Financial Year	Turnover in Lakhs(Rs.)
1.	2014-15	
2.	2015-16	
3.	2016-17	
TOTAL		Rs.....Lakhs
Average Turnover per annual		Rs.....Lakhs

It is certified that M/S …….. (Name of company and address) having factory at ……(address of factory) have required plant(s), machinery/machineries, building(s) & other infrastructure to manufacture the drugs. It is also certified that the statement is true and correct.

(III) It is certified that M/s _____ has Production & financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

Or (**ONLY i**n **case of IMPORTER**)

It is certified that M/s _____ has Financial capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

(IV) Further, It is certified that M/S ……is Micro and Small Enterprises (MSE) and registered with Director of Industries of concerned State/UT or appropriate authorities for quoted drugs against BPPI tender No. BPPI/Drug-065/2018 and eligible for exemption of paying EMD. This MSMEs is owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs.

(V) They have manufactured & marketed 2 or more commercial batches of each quoted drugs in last three years.

Or (**ONLY i**n **case of IMPORTER**)

They have marketed 2 or more commercial batches of each quoted drugs in last three years**.**

Date

(Name, Signature & Stamp)
Registration no.

NOTE

(i) Strike which is not applicable in above certificate.

(ii) MSEs would be treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

ANNEXURE – V

Ref. Clause 4.1 (p)

CHECK-LIST (Whether Uploaded the documents)

COVER – A

S.N.	Check List	YES /NO	Please indicate Page nos.
1	Check list - ANNEXURE – V		
2	EMD Rs. 10,00,000/- in the form of **Bank Guarantee or Bankers Cheque or Demand Draft** uploaded as per **ANNEXURE-III** DD No……Dated……..issued by ……(name of bank) and **delivered to BPPI**.Uploaded NSIC or MSME certificate for exemption if any.		
3	Scanned copy of Valid WHO-GMP (World Health Organisation-Good Manufacturing Practices) Certificate of manufacturing company. In case of imported drugs, scanned copy Valid WHO-GMP (World Health Organisation-Good Manufacturing Practices) Certificate of manufacturing company of foreign company.		
4	Scanned copy of Valid License for the Product duly approved by the Licensing Authority for each and every product quoted		
5	Scanned copy of valid GS1 registration certificate for bar coding		
6	Scanned copy of Valid Import License, if Imported and whole sale Drug license		
7	Scanned copy of Non Conviction Certificate issued by the licensing authority not older than 6 months.		
8	Scanned copy of Market Standing Certificate issued by the Licensing Authority		
9	Valid COPP certificate as per WHO format of their Principal Manufacturing company including Imported drugs, if any.		
10	Copies of **approval of Manufacturing Unit of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa , if any.		
11	Scanned copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs.		
12	Scanned copy of complete stability data (long term stability studies and accelerated stability studies) for all quoted drugs. If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be uploaded along with licensing agreement.		
13	Scanned copy of declaration of active API polymorphic form used in formulation of each quoted drugs and declare that it is internationally accepted active polymorph. **The Scanned copy of documented evidence should be uploaded.**		
14	Authorization letter nominating a responsible Person of the tenderer to transact the business with the Tender inviting Authority.		
15	Scanned copy of ANNEXURE –II (Declaration for eligibility in participating the tender) **original Annexure II delivered to BPPI.**		
16	Scanned copy of ANNEXURE IV{certificate from the C.A.(Chartered Accountant) or Company Secretary .		
17	Scanned copy of ANNEXURE-VIII (Details for Shelf life, Manufacturing Capacity & Batch Size)		
18	Scanned copy of ANNEXURE—XIII (Mandate form)		

NOTE : (i) Please ensure that page no. for document have been indicated.

(ii)EMD instrument and ANNEXURE II are to be delivered in original to BPPI, New Delhi before stipulated time and date.

Name and signature of authorised signatory (with company seal) ……

ANNEXURE –VI (Ref:-Clause 7.1)

MODEL BANK GUARANTEE FORMAT FOR FURNISHING EMD

Whereas …… (hereinafter called the

"tenderer") has submitted their offer dated…… for the supply

Of Drugs (hereinafter called the "tender") against the purchaser's tender enquiry No. BBPI/DRUG-065/2018 KNOW ALL MEN by these presents that WE …… of …….. having our registered office at …… are bound unto Bureau of Pharma Public Sector Undertakings of India New Delhi(hereinafter called the "Purchaser) in the sum of Rs. One lakh only for which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this…… day of …….201..

THE CONDITIONS OF THIS OBLIGATION ARE:

(1) If the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of this tender.

(2) If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity:-

a) If the tenderer fails to furnish the Performance Security for the due performance of the contract.

b) Fails or refuses to accept/execute the contract.

WE undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to 31.05.2019 and any demand in respect thereof should reach the Bank not later than the above date.

…….

(Signature of the authorized officer of the Bank)

…… ……

Name and designation of the officer

…….

Seal, name & address of the Bank and address of the Branch

Annexure -VII

Clause 8.1 &8.2

Bureau of Pharma Public Sector Undertakings of India, New Delhi
Tender for supply of drugs (Tender No. BPPI/DRUG-065/2018 dated 03/08/2018)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	**Drug Code**	**Generic name of Drugs**	**Unit Size**	**Pack Size**	**Packing per Carton (Shipper Pack)**	**Tender quantity in unit size**
1.	12	Etoricoxilb Tablets IP 120mg	10's	10's X 10	(10's X 10) X 10	381500
2.	13	Etoricoxilb Tablets IP 90mg	10's	10's X 10	(10's X 10) X 10	767500
3.	17	Indomethacin 25 mg	10's	10's X 10	[(10's x 10) x 10] x 10	40000
4.	20	Nimesulide BP 100 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	690000
5.	26	Tramadol Hcl 100 mg Inj.	2ml Amp	2ml X 10	[(2ml X 10) X 10] X 10	334000
6.	27	Tramadol HCl Injection 50mg 1 ml	1 ml Amp	1's X 10	[(1's X 10) X 10] X 10	149000
7.	28	Tramadol 50 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	756000
8.	33	Glimepiride 2 mg + Metformin HCL 500 mg SR Tablets	15's	15's X 10	[(15's x 10) x 10] x 10	21506000
9.	40	Amoxycillin 250mg + Cloxacillin 250 mg Caps	10's	10's X 10	[(10's x 10) x 10] x 10	238000
10.	43	Amoxycillin 125mg/ 5ml Dry Syrup	60 ml	60 ml X 10	(60ml X 10) X 10	534000
11.	49	Azithromycin 250 mg film coated Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	751000
12.	54	Cefixime film coated Tablets IP 100mg	10's	10's X 10	[(10's x 10) x 10] x 10	785000
13.	67	Ceftazadime 1000 mg Inj.	Vial & wfi	1's x 10	(1's x 10) x 50	67500

14.	82	Cephalexin Capsules IP 500mg	10's	10's X 10	[(10's x 10) x 10] x 10	109000
15.	87	Clotrimazole 1% w/w cream	15 Gm Tube	1's x 10	(1's x 10) x 50	853000
16.	88	Co-trimoxazole (Sulphamethoxazole 200 mg + Trimethoprim 40mg / 5ml) Susp	50 ml	50 ml x 10	(50 ml x 10) X 10	131000
17.	90	Co-trimoxazole- Pead. (20 mg + 100 mg) Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	56000
18.	96	Levofloxacin film coated Tablets IP 500mg	10's	10's X 10	[(10's x 10) x 10] x 10	874998
19.	110	Adapalene 0.1%w/v Ointment	15 Gm Tube	1's x 10	(1's x 10) x 50	271000
20.	119	Fluconazole Tablets 150 mg Film Coated Capsule	10's	10's X 10	[(10's x 10) x 10] x 10	1577000
21.	123	Lignocaine 2% w/w Ointment	30 g tube	1's X 20	(1's X 20) X 10	27000
22.	124	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/ Jar	250 gm x 1	(250 gm x 1) x 25	303500
23.	125	Povidone Iodine 5%w/w Ointment	15 Gm Tube	1's x 10	(1's x 10) x 50	1938500
24.	129	Povidone Iodine 7.5% Solution	500 ml	1's x 10	(1's x 10) x 5	4000
25.	131	Silver Sulphadiazine 1% w/w Cream_20 gm	20 gm Tube	1's x 20	(1's x 20) x 20	72000
26.	132	Silver Sulphadiazine 1% w/w cream_500 gm	500 gm	500 gm x 1	(500 gm x 1) x 20	10000
27.	138	Glimeperide Tablets IP 2mg	10's	10's X 10	[(10's x 10) x 10] x 10	7284500
28.	142	INSULIN INJECTION IP 40 IU/ml (Insulin Human Recombinant)	10 ml Vial	10 ml Vial X10	(10 ml Vial x 10) x 20	545000
29.	156	Doxorubicin Injection IP 50mg	Vial	1's x 10	(1's x 10) x 20	17500
30.	158	Etoposide 100 mg/5ml Inj.	Vial	1's x 10	(1's x 10) x 100	1000
31.	159	Gemcitabine 1000 mg Inj.	Vial	1's x 10	(1's x 10) x 20	2000

32.	160	Gemcitabine Injection IP 200mg	Vial	1's x 10	(1's x 10) x 20	28500
33.	162	Raloxifene Tablets strength 60 mg	10's	10's X 10	[(10's x 10) x 10] x 10	88000
34.	165	Ciprofloxacin (2mg/ml) Infusion	100 ml	100 ml X 6	(100 ml X 6) X 10	190000
35.	169	Levofloxacin 500 mg Infusion	100 ml	100 ml X 6	(100 ml X 6) X 10	12000
36.	174	Plasma Volume Expander (Gelatin Base)	500 ml	500 ml x 1	(500 ml x 1) x 20	55000
37.	175	Ringer Lactate (RL)	500 ml	1's	1's X 25	42000
38.	178	ALBENDAZOLE 400 mg + IVERMECTIN 6 mg Tablets	1's	1's X 10	(1 X 10) X 100	938000
39.	179	Albendazole Tablets IP 400MG	10's	10's X 10	[(10's x 10) x 10] x 10	373000
40.	180	Bisacodyl Tablets IP 5mg	10's	10's X 10	[(10's x 10) x 10] x 10	1002000
41.	181	TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml SYRUP	200 ml	1's x 10	(1's x 10) X 6	319000
42.	187	Domperidone 5 mg. / 5 ml Susp	30 ml	1's x 10	(1's X 10) x 20	98800
43.	191	Famotidine 20 mg Tab	14's	14's x 10	[(14's x 10) X 10] X 10	189000
44.	193	Furazolidone IP 100 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	23000
45.	194	Hyoscine Butyl Bromide 10 mg film coated Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	465000
46.	199	Metoclopramide 10 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	57000
47.	203	Misoprostol 200 mcg film coated Tablet	4's	4's x 10	(4's x 10) x 100	101500
48.	207	Omeprazole 20 mg capsules	10's	10's X 10	[(10's x 10) x 10] x 10	3804000
49.	213	Pantoprazole Injection 40mg	Vial & Wfi	1's x 10	(1's x 10) x 50	877000

50.	219	Calcium + Vitamin D3 Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	1501000
51.	225	Syrup of Iron and Folic Acid in a flavoured Base	200 ml	1's x 10	(1's x 10) X 6	528000
52.	226	Iron(carbonil Iron)100 mg+Folic Acid 1.5 mg+Zinc Capsules	15's	15's X 10	[(15's x 10) x 10] x 10	383000
53.	227	Polyvitamin (Prophylactic) NFI	10's	10's X 10	[(10's x 10) x 10] x 10	2435000
54.	233	Vitamin-C Chewable 100mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	1447000
55.	236	Budesonide 100 mcg/dose Inhaler	200 MDI	1's X 10	(1's x 10) x 20	163000
56.	240	Cetrizine 10mg film coated Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	5760000
57.	244	Etophyllin and Theophylline Inj. (84.7mg+25.3 mg) mg/2ml	2 ml Amp	2ml x 10	[(2ml X 10) X 10] X 10	787000
58.	248	Levocetrizine film coated Tablets IP 5mg	10's	10's X 10	[(10's x 10) x 10] x 10	5557000
59.	256	Salbutamol Tablets IP 2mg	10's	10's X 10	[(10's x 10) x 10] x 10	1097000
60.	264	Amlodipine Tablets IP 5mg	10's	10's X 10	[(10's x 10) x 10] x 10	5906000
61.	281	Heparin Sodium 5000iu/ ml Inj.	5 ml	5 ml X 10	[(5 ml X 10) X 10] X 10	18000
62.	301	Tranexamic Acid Tablets IP 500 mg	10's	10's X 10	[(10's x 10) x 10] x 10	310000
63.	304	Arteether 150mg inj	2ml Vial	2ml X 10	[(2ml X 10) X 10] X 10	145500
64.	314	Alprazolam 0.5 mg Uncoated Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	2388000
65.	323	Flunarizine 10 mg Tabs	10's	10's X 10	[(10's x 10) x 10] x 10	1047500
66.	325	Fluoxetine Hydrochloride Capsules IP 20mg	10's	10's X 10	[(10's x 10) x 10] x 10	334000
67.	331	THYROXINE SODIUM TABLETS IP 50 µg	10's	10's X 10	[(10's x 10) x10] x 20	1842000

68.	333	Dexamethasone 0.5 mg Tablets	10's	10's X 10	[(10's x 10) x10] x 20	940000
69.	352	Bupivacaine Hydrochloride 0.5% w/w Inj.	20ml	20 ml x 5	[(20ml x 5) x 10] x 10	22000
70.	357	Lignocaine 1% + Adrenaline 2%w/v Inj.	30 ml Vial	1's x 10	(1's x 10) X 10	50000
71.	359	Tetanus Toxoid Inj.	0.5 ml Amp.	1's x 10	(1's x10) x 20	149000
72.	367	VOGLIBOSE Tablets IP 0.3 mg	10's	10's X 10	[(10's x 10) x 10] x 10	2270000
73.	368	GLICLAZIDE TABS SR 60 MG	10's	10's X 10	[(10's x 10) x 10] x 10	1147000
74.	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's	6's X 10	[(6's X 10) X 10] X 10	42000
75.	378	Anti T. B. 4 Kit	1's	1's X 10	(1 X 10) X 100	66000
76.	384	ITRACONAZOLE Capsules 100 mg	4's	4's x 10	(4's x 10) x 100	4246000
77.	387	TERBINAFINE 250 MG TABLETS	7's	7's x 10	[(7's x 10) x 10] x 10	1226550
78.	388	Anti T. B. 3 Kit	1's	1's X 10	(1 X 10) X 100	59000
79.	389	PENICILLIN G 400000 IU TABLETS	6's	6's X 10	[(6's X 10) X 10] X 10	47000
80.	391	MOXIFLOXACIN TABLETS 400 MG	5's	5's X 10	[(5's X 10) X 10] X 10	543000
81.	392	GRISEOFULVIN TABLETS IP 250 MG	10's	10's X 10	[(10's x 10) x 10] x 10	182000
82.	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's	5's X 10	[(5's X 10) X 10] X 10	257000
83.	396	AMPHOTERICIN B INJECTION IP. 50MG/ML	20 ml Vial	1's x 10	(1's X 10) X 100	4000
84.	398	RIFAMPICIN TABLETS IP 450 MG	10's	10's X 10	[(10's x 10) x 10] x 10	8000
85.	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's	10's X 10	[(10's x 10) x 10] x 10	54000

86.	400	Ketoconazole Tablets IP 200 mg	10's	10's X 10	[(10's x 10) x 10] x 10	751600
87.	407	IVERMECTIN TABLETS 12 MG	10's	10's X 10	[(10's x 10) x 10] x 10	333000
88.	408	BENZYLPENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL	1's x 5	[(1's x 5) x 10] x10	9000
89.	409	BENZYLPENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL	1's x 5	[(1's x 5) x 10] x10	9000
90.	410	TRASTUZUMAB INJECTION 440 MG with WFI	Vial with WFI	1's X 10	(1's X 10) x 10	2000
91.	411	BEVACIZUMAB INJECTION 25 MG	1's Vial	1's X 10	(1's X 10) x 10	1000
92.	412	AZATHIOPRINE TABLETS IP 50 MG	10's	10's X 10	[(10's x 10) x 10] x 10	51000
93.	413	METHOTREXATE TABLETS IP 7.5 MG	10's	10's X 10	[(10's x 10) x 10] x 10	30000
94.	414	TRANEXAMIC ACID 500 mg+ MEFENAMIC ACID 250 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	168500
95.	415	GLYCERYL TRINITRATE TABLETS IP 2.6 mg	25's	25's x 10	(25's x10) x10	98000
96.	419	HEPARIN SODIUM 50 IU + Benzyl Nicotinate 2 mg/ 1 gm Ointment/Cream	20 gm Tube	1's x 20	(1's x 20) x 20	45000
97.	422	TORASEMIDE Tablets 10 mg	15's	15's X 10	[(15's x 10) x 10] x 10	1010500
98.	426	ACENOCOUMAROL TABLETS 2 MG	30's	30's X 10	[(30's X 10) X 10] X 10	345000
99.	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's	30's X 10	[(30's X 10) X 10] X 10	72000
100.	436	TELMISARTAN 40 mg+ CHLORTHALIDONE 12.5 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	1046500
101.	439	OLMESARTAN MEDOXOMIL 40 mg + HYDROCLORTHIAZIDE 12.5 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	2365000

102.	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's	30's X 10	[(30's X 10) X 10] X 10	32000
103.	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	1800000
104.	447	MOXONIDINE TABLETS 0.3 MG	10's	10's X 10	[(10's x 10) x 10] x 10	60000
105.	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	187000
106.	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	48000
107.	455	VERAPAMIL TABLETS IP 80 MG	10's	10's X 10	[(10's x 10) x 10] x 10	6000
108.	457	TORASEMIDE TABLETS IP. 20 MG	10's	10's X 10	[(10's x 10) x 10] x 10	744500
109.	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 g tube	1's X 20	(1's X 20) X 10	32000
110.	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's	10's X 10	[(10's x 10) x 10] x 10	202000
111.	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ml	5 ml X 10	[(5 ml X 10) X 10] X 10	58000
112.	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ml	1's x 10	(1's x 10) X 6	259000
113.	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML SUSPENSION 170ml	170 ml Bottle	1's X 10	(1's x 10) X 6	521000
114.	481	RIFAXIMIN TABLETS BP 400 MG	10's	10's X 10	[(10's x 10) x 10] x 10	27000
115.	483	LOPERAMIDE Capsules IP 2 mg	10's	10's X 10	[(10's x 10) x 10] x 10	1248000
116.	484	ESOMEPRAZOLE Tablets IP 40 mg (ENTERIC COATED)	10's	10's X 10	[(10's x 10) x 10] x 10	1921700
117.	485	PROMETHAZINE (FILM COATED)	10's	10's X 10	[(10's x 10) x 10]	521000

		Tablets IP 25 mg			x 10	
118.	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	39000
119.	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's	10's X 10	[(10's x 10) x 10] x 10	322000
120.	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's	10's X 10	[(10's x 10) x 10] x 10	34000
121.	490	SIMETHICONE 40 MG DROPS	15 ML	1's X 10	(1's x 10) x 50	3000
122.	494	ISPAGHULA HUSK IP 100 GM	100 GM	100gm x 10	(100gm x 10) x 10	46000
123.	496	DYDROGESTERONE TABLETS IP 10 MG	10's	10's X 10	[(10's x 10) x 10] x 10	30000
124.	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	2213500
125.	500	LEVO-THYROXINE SODIUM TABLETS IP 100 MCG	100's	1's X 10	(1's x 10) x 50	1118000
126.	502	DEFLAZACORT Tablets 6 mg	6's	6's X 10	(6's X 10) X 10	1737000
127.	505	CARBIMAZOLE TABLETS IP 10 MG	100's	1's X 10	(1's x 10) x 50	46000
128.	509	HYDROXYCHLOROQUINE Tablets IP 200 mg	10's	10's X 10	[(10's x 10) x 10] x 10	2508000
129.	510	PARACETAMOL 325 mg+ TRAMADOL 37.5 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	863000
130.	511	PARACETAMOL Tablets IP 650 mg	15's	15's X 10	[(15's x 10) x 10] x 10	9188000
131.	521	TRAMADOL TABLETS SR 100 MG	10's	10's X 10	[(10's x 10) x 10] x 10	376000
132.	523	NAPROXEN TABLETS IP 500 MG	15's	15's X 10	[(15's x 10) x 10] x 10	84000
133.	524	LIDOCAINE INJECTION IP 2 %W/V	30 ml Vial	1's x 10	(1's x 10) X 10	7000
134.	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ml Respules	2.5 ml x 5	[(2.5 ml x 5) X 4] x 50	27000

135.	530	FORMOTERAL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's	30's X 10	(30's X 10) X 10	31000
136.	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's	30's X 10	(30's X 10) X 10	18000
137.	534	SALBUTAMOL 400 MCG + BECLOMETHASONE 200 MCG RESPICAP	30's	30's X 10	(30's X 10) X 10	17000
138.	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ml	100 ml X 6	(100 ml X 6) X 10	37000
139.	538	THEOPHYLLINE TABLETS 400 MG	10's	10's X 10	[(10's x 10) x 10] x 10	33000
140.	539	ACETYLCYSTEINE Tablets 600 mg	10's	10's X 10	[(10's x 10) x 10] x 10	657000
141.	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ml Respules	2ml x 5	[(2ml x 5) X 4] x 50	40000
142.	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's	10's X 10	[(10's x 10) x 10] x 10	28000
143.	557	TIOTROPIUM ROTOCAP 18 MCG	15's	15's X 10	(15's X 10) x 10	19000
144.	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120 MD	1's x 10	(1's x 10) x 100	24000
145.	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's	30's X 10	[(30's X 10) X 10] X 10	33000
146.	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD	1's x 10	(1's x 10) x 100	113000
147.	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ml	100 ml X 6	(100 ml X 6) X 10	87000
148.	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML	10 ml x 10	(10 ml x 10) x 20	411000
149.	564	FORMOTERAL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's	15's X 10	(15's X 10) x 10	25000
150.	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's	15's X 10	(15's X 10) x 10	24000
151.	566	IPRATROPIUM 250 MCG/ML	15 ML	1's X 10	(1's x 10) x 50	15000

		I:SOLUTION				
152.	568	SALMETEROL 50 MCG+ FLUTICASONE PROPIONATE 250 MCG /PUFF INHALER	100 MD	1's x 10	(1's x 10) x 10	14000
153.	571	Tamsulosin 0.4 mg + Dutasteride 0.5 mg Tablets	15's	15's X 10	[(15's x 10) x 10] x 10	1638000
154.	574	VACCINE RABIES INJECTION 2.5 IU	1 ml Amp	1's X 10	(1's x 10) x 50	319000
155.	579	Multivitamin Capsule	20's	20's X 10	[(20's X 10) X 10] X 10	685000
156.	581	CALCIUM CARBONATE 500MG+CALCITRIOL 0.25 MCG + ZINC 7.5 MG Capsules	10's	10's X 10	[(10's x 10) x 10] x 10	6727000
157.	583	CYPROHEPTADINE Tablets IP 4 mg	10's	10's X 10	[(10's x 10) x 10] x 10	352000
158.	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's	30's X 10	[(30's X 10) X 10] X 10	303000
159.	586	METHYLCOBALAMIN 1500 MCG, L- CARTININE L- TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's	10's X 10	[(10's x 10) x 10] x 10	397000
160.	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML	1's X 10	(1's X 10) X 4	209000
161.	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's	10's X 10	[(10's x 10) x 10] x 10	5699000
162.	590	VITAMIN A, B-COMPLEX, D & E INJECTION	10 ml Vial	10 ml Vial X10	(10 ml Vial x 10) x 20	65000
163.	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ml Vial	10 ml Vial X10	(10 ml Vial x 10) x 20	75000
164.	594	GLUCOSE POWDER	75 gm	75 gm x 10	(75 gm x 10) x 10	354000
165.	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ml Amp	2ml x 10	[(2ml X 10) X 10] X 10	53000
166.	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML	1's X 10	(1's x 10) x 50	565000

167.	597	PYRIDOXINE TABLETS IP 50 MG	10's	10's X 10	[(10's x 10) x 10] x 10	40000
168.	598	PREGABALIN 75 mg+ METHYLCOBALAMIN 750 MCG Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	2085000
169.	603	Cetirizine Dihydrochloride IP 5mg, Phenylephrine HCl IP 10 mg, Paracetamol IP 325mg Tablets 10's	10's	10's X 10	[(10's x 10) x 10] x 10	1371000
170.	606	Cyproheptadine Tablets 4mg 10's	10's	10's X 10	[(10's x 10) x 10] x 10	48000
171.	609	Silver NO3 0.20%w/w, Chlorhexidine Gluconate Soln 0.20%, Preservative Chlorocresol 0.12%w/w,Cream	15 Gm Tube	1's x 10	(1's x 10) x 50	43000
172.	616	Celecoxib 100 mg capsules	10's	10's X 10	[(10's x 10) x 10] x 10	9000
173.	617	Celecoxib 200 mg capsules	10's	10's X 10	[(10's x 10) x 10] x 10	23000
174.	619	Cough Paed.Syp Dextromethorphan IP5 mg+Bromhexine4mg+Phenylpropanolamine10mg+Menthol IP 0.75mg/5ml	60 ml Bottle	60 ml X 10	(60ml X 10) X 10	37000
175.	621	Iron & Zinc(Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc	15's	15's X 10	[(15's x 10) x 10] x 10	3504000
176.	622	Cough lozenges Ginger / Lemon (2,4Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in flavour	8's	8's x 10	[(8's x 10) x 10] x 10	194000
177.	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's	8's x 10	[(8's x 10) x 10] x 10	1758000
178.	625	Cough Tablets Bromhexine HCl 8.00 mg Phenylephrine HCl 5.00 mg	15's	15's X 10	[(15's x 10) x 10] x 10	33000
179.	626	Ketoconazole Shampoo 2% W/V	100ml Bottle	100 ml X 6	(100 ml X 6) X 10	918500

180.	628	Etophylline IP 231mg. + Theophylline 69mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	300000
181.	629	Inhalent Softgel Caps(Camphor25mg+Clorothymol 5 mg+Eucalyptus130mg+Menthol 55mg+Turpentine oil110mg	10's	10's X 10	[(10's x 10) x 10] x 10	121000
182.	631	Etamsylate Tablets 500 mg.	10's	10's X 10	[(10's x 10) x 10] x 10	562000
183.	635	Clobetasol Proppionate BP0.05%w/wNeomycin IP0.50%w/wMiconazole IP2%w/wChlorocresol IP0.10 %w/wCream	10 gms tube	1's x 10	(1's x10) x 50	38000
184.	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone 250 mg film coated tab.	10's	10's X 10	[(10's x 10) x 10] x 10	1715500
185.	638	Aceclofenac 100 mg Paracetamol 325 mg Serratiopeptidase 15 mg	10's	10's X 10	[(10's x 10) x 10] x 10	628000
186.	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg Bromhexine 4 mg Guaiphenesin 50 mg Menthol 2	100 ml	100 ml X 6	(100 ml X 6) X 10	850000
187.	640	Nimesulide 1% W/W Gel	20 gm Tube	1's x 20	(1's x 20) x 20	402000
188.	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ML Bottles	60 ml X 10	(60ml X 10) X 10	116000
189.	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	52000
190.	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle	10ml X 10	(10ml X 10) X 50	180000
191.	650	Mefenamic Acid 500mg+Paracetamol 325 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	23000
192.	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental	225ml	1's X 10	(1's X 10) x 4	296000

		Calcium 82mg /5				
193.	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml	1's x 10	(1's x 10) X 6	105000
194.	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15 ml	1's X 10	(1's x 10) x 50	133000
195.	658	Chlorhexidine Gluconate 0.3%v/v+Cetrimide 0.6%w/v Antiseptic Liquid 100 ML	100 ml	100 ml X 6	(100 ml X 6) X 10	386500
196.	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin Soap	75 gm	75 gm x 10	(75 gm x 10) x 10	77000
197.	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion 100ml	100 ml	100 ml X 6	(100 ml X 6) X 10	62000
198.	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion 200ml	200 ml	1's x 10	(1's x 10) X 6	6000
199.	674	Sitaglptin 100 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	532000
200.	675	Sitaglptin 50 mg Tablet	10's	10's X 10	[(10's x 10) x 10] x 10	554000
201.	676	Triamcinolone Acetonide 0.1 % Mouth Ulcer gel	10gm	10gm X 20	(10gm X 20) X 20	36000
202.	678	levodopa 250mg & Carbidopa 25mg Tablets 10's	10's	10's X 10	[(10's x 10) x 10] x 10	91000
203.	679	Nalidixic Acid 500 mg Tablet	10's	10's X 10	[(10 x 10) x 10] x 5	31000
204.	681	Phenazopyridine Hcl 100mg tab	10's	10's X 10	[(10's x 10) x 10] x 10	5000
205.	682	Rabeprazole 20mg + Domperidone 10mg Capsule	10's	10's X 10	[(10's x 10) x 10] x 10	1739500
206.	693	Tropicamide Eye Drops	5 ml Vial	5ml x 10	[(5ml x 10) x 10)]x 10	14000
207.	695	Polymyxin B SO4 BP 5000 iu , Chloramphenicol IP 4mg Phenulmercuiric intrate IP Ear/Eye Drop	5 ml	5 ml x 10	[(5ml x 10) x 10)]x 10	8000

208.	696	Polymyxin-B BP5000iu,Chloramphenicol IP4mg ,Dexamethasone IP 1mgPhenulmercuiric IP Ear/Eye Drop	5 ml	5 ml x 10	[(5ml x 10) x 10)]x 10	8000
209.	700	Ketamine HCl 10 mg/ml Injection	20ml Vial	20 ml x 10	(20 ml x 10) x 50	17000
210.	701	Pilocar 2 % eye drop	10 ml Vial	10ml X 10	(10ml X 10) X 50	44000
211.	704	Cephalexin 125mg/5ml dry syrup	30 ml	1's x 10	(1's X 10) x 20	58000
212.	707	Piroxicam 10 mg tablets	10's	10's X 10	[(10's x 10) x 10] x 10	8000
213.	709	Piroxicam 20 mg with bezyl alcohol injection	1ml Amp	1 ml x 10	(1 ml x 10) x 20	13000
214.	710	Piroxicam 40 mg with bezyl alcohol injection	2ml Amp	2ml X 10	[(2ml X 10) X 10] X 10	9000
215.	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc SO4 0.1 % w/w cream/onit	10 gm	10 gm X 20	(10 gm x 20) x 20	248000
216.	717	Etodolac Tablets IP 300mg 10's	10's	10's X 10	[(10's x 10) x 10] x 10	303000
217.	721	Water for Injection amp polypack 2ml	2ml Amp	2ml X 10	[(2ml X 10) X 10] X 10	16000
218.	722	Water for Injection amp polypack 5 ml	5ml	5 ml x 10	[(5 ml X 10) X 10] X 10	40000
219.	724	Whey Peptide based Internal nutrition ProtinFatCarbsVitADEKCBcomplexMineralCholine TaurineCarnitine	200 gm Tin	200gm x 1	(200gm x1) x 50	27000
220.	732	Sodium Chloride Injection IP 0.9%w/v (Normal Saline (NS) 0.9% w/v) using FFS technology	100ml IV fluid plastic contai	1's X 20	(1's X 20) X 5	237000
221.	747	Glimepiride Tablets 3mg	10's	10's X 10	[(10's x 10) x 10] x 10	986000
222.	749	Cholecalciferol-60000 iu	1gm	1gm x 10	[(1gm x 10) x 10]	180000

		granules	sachet		x 10	
223.	816	Calcium Acetate Tablets 667mg	10's	10's X 10	[(10 x 10) x 10] x 5	1793000
224.	817	Calcium Carbonate 1250 Mg Vitamin D3 250 Iu Magnesium Oxide 40 Mg Manganese Sulphate 1.8 Mg Zinc	10's	10's X 10	[(10 x 10) x 10] x 5	4584000
225.	830	Chlordiazepoxide10mg+ Trifluoperazine 1mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	309000
226.	832	Chlorthalidone Tablets 12.5mg	10's	10's X 10	[(10's x 10) x 10] x 10	1331000
227.	837	Cilnidipine Tablets 20mg	10's	10's X 10	[(10's x 10) x 10] x 10	1848000
228.	864	Dextrose Injection IP 25%w/v	100 ml	100 ml X 6	(100 ml X 6) X 10	36000
229.	884	Erythromycin Estolate Suspension 125 Mg/5ml	60ml	60 ml X 10	(60ml X 10) X 10	59000
230.	893	Filgrastim 300mcg/1ml Prefilled Syringe	1's	1's X 10	(1's X 10) X 10	25000
231.	900	Gabapentin 100mg Methylcobalamine 500mcg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	1095000
232.	906	Glyceryl Trinitrate Tablets IP 2.6mg (Nitroglycerin Tablets)	30's	30's X 10	(30's X 10) X 10	1397000
233.	909	Human Albumin Solution 20%	100ml vial	1's X 10	(1's x10)x10	61000
234.	915	Hydroxyzine HCl Tablets IP 10mg	10's	10's X 10	[(10's x 10) x 10] x 10	1290000
235.	931	Lamotrigine Tablets IP 100mg	10's	10's X 10	[(10's x 10) x 10] x 10	134000
236.	933	Leflunomide Tablets IP 20mg	10's	10's X 10	[(10's x 10) x 10] x 10	242000
237.	936	Leuprolide Acetate Injections 3.75mg	1's	1's X 10	(1's X 10) X 10	13000
238.	937	Levetiracetam Syrup100 Mg/5ml	100 ml	100 ml X 6	(100 ml X 6) X 10	20000

239.	938	Levocarnitine Injections 1gm	5ml Vial	5ml X 10	[(5 ml X 10) X 10] X 10	18000
240.	939	Levocarnitine Tablets 500mg	10's	10's X 10	[(10's x 10) x 10] x 10	357000
241.	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	20 gm Tube	1's x 20	(1's x 20) x 20	110000
242.	951	Lycopene 1000 Mcg Vitamin A Palmitate 2500 Iu Vitamin E Acetate 10 Iu Selenium 35 Mcg Vitamin C	200 ml	1's x 10	(1's x 10) X 6	659000
243.	960	Metformin SR Tablets IP 850mg	10's	10's X 10	[(10's x 10) x 10] x 10	2486000
244.	974	Natural Micronised Progesterone Capsules 100mg	10's	10's X 10	[(10's x 10) x 10] x 10	71000
245.	999	Paroxetine SR Tablet 37.5mg	10's	10's X 10	[(10's x 10) x 10] x 10	388000
246.	1005	Phenobarbitone Tablets I.P 30mg	30's	30's X 10	(30's X 10) X 10	126000
247.	1041	Risperidone 4mg, Trihexiphenidyl 2mg Tab.	10's	10's X 10	[(10's x 10) x 10] x 10	449000
248.	1051	Sertraline Tablets I.P 25mg	10's	10's X 10	[(10's x 10) x 10] x 10	388000
249.	1059	Sodium Valproate EC Tablets I.P 200mg	10's	10's X 10	[(10's x 10) x 10] x 10	451000
250.	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	10ml	1's x10	[(1's x10) x 10] x 10	2000
251.	1098	Voglibose 0.2mg, Metformin 500mg SR Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	4418000
252.	1123	Clomipramine Hydrochloride SR Tablets 75mg	10's	10's X 10	[(10's x 10) x 10] x 10	514000
253.	1125	Aripiprazole Tablets 5mg	10's	10's X 10	[(10's x 10) x 10] x 10	566000
254.	1129	Teneligliptin 20mg + Metformin 500mg Tablet SR	10's	10's X 10	[(10's x 10) x 10] x 10	1735000
255.	1149	Lisinopril 10mg Tabs	15's	15's X 10	[(15's x 10) x 10] x 10	513000
256.	1156	METOPROLOL 25 MG +	7's	7's x 10	[(7's x 10) x 10] x	993000

		AMLODIPINE 5 MG TABLETS			10	
257.	1164	NANDROLONE DECANOATE INJECTION IP 50 mg/ml	2 ml Amp	2ml x 10	[(2ml X 10) X 10] X 10	158000
258.	1178	5-Flurouracil Inj. 500mg	10 ml Vial	1's x10	[(1's x10) x 10] x 10	13000
259.	1181	Carboplatin Injection 150mg	15 ML Vial	1's x10	(1's X 10) X 10	8500
260.	1210	Bendamustine 100 mg Injection	VIAL	1's X 10	(1's X 10) x 10	5000
261.	1213	Erlotinib 150 mg Tablet	10's Bottle	10's X 10	(10's X 10) X 10	3000
262.	1214	Gefitinib 250 mg Tablets	10's	10's X 10	[(10's x 10) x 10] x 10	7000
263.	1215	Pemetrexed 100 mg Injection	VIAL	1's X 10	(1's X 10) x 10	1000
264.	1216	Pemetrexed 500 mg Injection	VIAL	1's X 10	(1's X 10) x 10	1000
265.	1224	Povidone-Iodine 10% antiseptic paint	50 ml	50 ml x 10	(50 ml x 10) X 10	20000
266.	1229	Levosalbutamol+Ipratropium(2.5 +500)mcg Respules	2.5 ml Respu les	2.5 ml x 5	[(2.5 ml x 5) X 4] x 50	14000
267.	1232	Noscapine 1.83mg/5ml Syp	50 ml	50 ml x 10	(50 ml x 10) X 10	6000
268.	1237	Methyldopa tabs 500mg	10's	10's X 10	(10's X 10) X 10	16000
269.	1238	Prazosin Tablets 2.5mg "SR" Tab	30's	30's X 10	[(30's X 10) X 10] X 10	46000
270.	1239	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets,15's	15's	15's X 10	[(15's x 10) x 10] x 10	986000
271.	1241	Cefaclor Tablet I.P 250 mg tabs	10's	10's X 10	[(10's x 10) x 10] x 10	18000
272.	1242	Cefaclor Tablet I.P 375 mg tabs	10's	10's X 10	[(10's x 10) x 10] x 10	19000
273.	1243	Betamethasone 0.05% w/w + Salicylic acid 3% w/w cream	20 gm Tube	1's x 20	(1's x 20) x 20	38000

Annexure – VIII

{Ref:- clause 8.1(ii)}

(1)	(2)	(3)	(4)	(5)	(6)	(7)
Sr. No.	**Drug Code**	**Generic name of Drug**	**Unit Size**	**Shelf Life in months**	**Manufacturing Capacity per year in Units**	**Manufacturing Batch Size in Units**
1	12	Etoricoxilb Tablets IP 120mg	10's			
2	13	Etoricoxilb Tablets IP 90mg	10's			
3	17	Indomethacin 25 mg	10's			
4	20	Nimesulide BP 100 mg Tablet	10's			
5	26	Tramadol Hcl 100 mg Inj.	2ml Amp			
6	27	Tramadol HCl Injection 50mg 1 ml	1 ml Amp			
7	28	Tramadol 50 mg Tablet	10's			
8	33	Glimepiride 2 mg + Metformin HCL 500 mg SR Tablets	15's			
9	40	Amoxycillin 250mg + Cloxacillin 250 mg Caps	10's			
10	43	Amoxycillin 125mg/ 5ml Dry Syrup	60 ml			
11	49	Azithromycin 250 mg film coated Tablet	10's			
12	54	Cefixime film coated Tablets IP 100mg	10's			
13	67	Ceftazadime 1000 mg Inj.	Vial & wfi			
14	82	Cephalexin Capsules IP 500mg	10's			
15	87	Clotrimazole 1% w/w cream	15 Gm Tube			
16	88	Co-trimoxazole (Sulphamethoxazole 200 mg + Trimethoprim 40mg / 5ml) Susp	50 ml			
17	90	Co-trimoxazole- Pead. (20 mg + 100 mg) Tablet	10's			
18	96	Levofloxacin film coated Tablets IP 500mg	10's			
19	110	Adapalene 0.1%w/v Ointment	15 Gm Tube			
20	119	Fluconazole Tablets 150 mg Film Coated Capsule	10's			
21	123	Lignocaine 2% w/w Ointment	30 g tube			
22	124	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/Jar			
23	125	Povidone Iodine 5%w/w Ointment	15 Gm Tube			
24	129	Povidone Iodine 7.5% Solution	500 ml			
25	131	Silver Sulphadiazine 1% w/w Cream_20 gm	20 gm Tube			
26	132	Silver Sulphadiazine 1% w/w cream_500 gm	500 gm			
27	138	Glimeperide Tablets IP 2mg	10's			
28	142	INSULIN INJECTION IP 40 IU/ml (Insulin Human	10 ml			

		Recombinant)	Vial			
29	156	Doxorubicin Injection IP 50mg	Vial			
30	158	Etoposide 100 mg/5ml Inj.	Vial			
31	159	Gemcitabine 1000 mg Inj.	Vial			
32	160	Gemcitabine Injection IP 200mg	Vial			
33	162	Raloxifene Tablets strength 60 mg	10's			
34	165	Ciprofloxacin (2mg/ml) Infusion	100 ml			
35	169	Levofloxacin 500 mg Infusion	100 ml			
36	174	Plasma Volume Expander (Gelatin Base)	500 ml			
37	175	Ringer Lactate (RL)	500 ml			
38	178	ALBENDAZOLE 400 mg + IVERMECTIN 6 mg Tablets	1's			
39	179	Albendazole Tablets IP 400MG	10's			
40	180	Bisacodyl Tablets IP 5mg	10's			
41	181	TRICHOLINE CITRATE 275 mg+ CYPROHEPTADINE HCl 2 mg/5ml SYRUP	200 ml			
42	187	Domperidone 5 mg. / 5 ml Susp	30 ml			
43	191	Famotidine 20 mg Tab	14's			
44	193	Furazolidone IP 100 mg Tablet	10's			
45	194	Hyoscine Butyl Bromide 10 mg film coated Tablet	10's			
46	199	Metoclopramide 10 mg Tablets	10's			
47	203	Misoprostol 200 mcg film coated Tablet	4's			
48	207	Omeprazole 20 mg capsules	10's			
49	213	Pantoprazole Injection 40mg	Vial & Wfi			
50	219	Calcium + Vitamin D3 Tablet	10's			
51	225	Syrup of Iron and Folic Acid in a flavoured Base	200 ml			
52	226	Iron(carbonil Iron)100 mg+Folic Acid 1.5 mg+Zinc Capsules	15's			
53	227	Polyvitamin (Prophylactic) NFI	10's			
54	233	Vitamin-C Chewable 100mg Tablet	10's			
55	236	Budesonide 100 mcg/dose Inhaler	200 MDI			
56	240	Cetrizine 10mg film coated Tablet	10's			
57	244	Etophyllin and Theophylline Inj. (84.7mg+25.3 mg) mg/2ml	2 ml Amp			
58	248	Levocetrizine film coated Tablets IP 5mg	10's			
59	256	Salbutamol Tablets IP 2mg	10's			
60	264	Amlodipine Tablets IP 5mg	10's			
61	281	Heparin Sodium 5000iu/ ml Inj.	5 ml			
62	301	Tranexamic Acid Tablets IP 500 mg	10's			
63	304	Arteether 150mg inj	2ml Vial			
64	314	Alprazolam 0.5 mg Uncoated Tablet	10's			
65	323	Flunarizine 10 mg Tabs	10's			
66	325	Fluoxetine Hydrochloride Capsules IP 20mg	10's			
67	331	THYROXINE SODIUM TABLETS IP 50 µg	10's			
68	333	Dexamethasone 0.5 mg Tablets	10's			
69	352	Bupivacaine Hydrochloride 0.5% w/w Inj.	20ml			
70	357	Lignocaine 1% + Adrenaline 2%w/v Inj.	30 ml Vial			

71	359	Tetanus Toxoid Inj.	0.5 ml Amp.			
72	367	VOGLIBOSE Tablets IP 0.3 mg	10's			
73	368	GLICLAZIDE TABS SR 60 MG	10's			
74	374	ARTEMETHER 80 MG + LUMEFANTRINE 480 MG SR TABLETS	6's			
75	378	Anti T. B. 4 Kit	1's			
76	384	ITRACONAZOLE Capsules 100 mg	4's			
77	387	TERBINAFINE 250 MG TABLETS	7's			
78	388	Anti T. B. 3 Kit	1's			
79	389	PENICILLIN G 400000 IU TABLETS	6's			
80	391	MOXIFLOXACIN TABLETS 400 MG	5's			
81	392	GRISEOFULVIN TABLETS IP 250 MG	10's			
82	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	5's			
83	396	AMPHOTERICIN B INJECTION IP. 50MG/ML	20 ml Vial			
84	398	RIFAMPICIN TABLETS IP 450 MG	10's			
85	399	RIFAMPICIN, ISONIAZIDE and PYRAZINAMIDE TABLETS IP (120MG+50MG+300MG)	10's			
86	400	Ketoconazole Tablets IP 200 mg	10's			
87	407	IVERMECTIN TABLETS 12 MG	10's			
88	408	BENZYLPENICILLIN INJECTION IP 0.6 MILLION UNITS	VIAL			
89	409	BENZYLPENICILLIN INJECTION IP 1.2 MILLION UNITS	VIAL			
90	410	TRASTUZUMAB INJECTION 440 MG with WFI	Vial with WFI			
91	411	BEVACIZUMAB INJECTION 25 MG	1's Vial			
92	412	AZATHIOPRINE TABLETS IP 50 MG	10's			
93	413	METHOTREXATE TABLETS IP 7.5 MG	10's			
94	414	TRANEXAMIC ACID 500 mg+ MEFENAMIC ACID 250 mg Tablets	10's			
95	415	GLYCERYL TRINITRATE TABLETS IP 2.6 mg	25's			
96	419	HEPARIN SODIUM 50 IU + Benzyl Nicotinate 2 mg/ 1 gm Ointment/Cream	20 gm Tube			
97	422	TORASEMIDE Tablets 10 mg	15's			
98	426	ACENOCOUMAROL TABLETS 2 MG	30's			
99	433	ISOSORBIDE MONONITRATE TABLETS IP 30 MG	30's			
100	436	TELMISARTAN 40 mg+ CHLORTHALIDONE 12.5 mg Tablets	10's			
101	439	OLMESARTAN MEDOXOMIL 40 mg + HYDROCLORTHIAZIDE 12.5 mg Tablets	10's			
102	444	ENALAPRIL 10 MG + HYDROCLORTHIAZIDE 25 MG TABLETS	30's			
103	446	AMLODIPINE 5 MG + HYDROCHLOROTHIAZIDE 12.5 MG TABLETS	10's			
104	447	MOXONIDINE TABLETS 0.3 MG	10's			
105	448	AMLODIPINE 5 MG+ RAMIPRIL 5 MG TABLETS	10's			
106	453	BISOPROLOL 5 MG+ HYDROCHLOROTHIAZIDE 6.25 MG TABLETS	10's			

107	455	VERAPAMIL TABLETS IP 80 MG	10's			
108	457	TORASEMIDE TABLETS IP. 20 MG	10's			
109	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12w/w+3%w/w)	30 g tube			
110	464	DICYCLOMINE 10 MG + PARACETAMOL 325 MG + TRAMADOL 50 MG CAPSULES	10's			
111	468	BACILLUS CLAUSII SPORES ORAL SUSPENSION 2 Billion/ 5 ML	5 ml			
112	470	PEPSIN 10 MG+ DIASTASE 50 MG ORAL LIQUID /5 ML	200 ml			
113	476	LIQUID PARAFFIN 1.25 ML+ MILK OF MAGNESIA 3.75ML+ SODIUM PICOSULPHATE 3.33MG /5ML SUSPENSION 170ml	170 ml Bottle			
114	481	RIFAXIMIN TABLETS BP 400 MG	10's			
115	483	LOPERAMIDE Capsules IP 2 mg	10's			
116	484	ESOMEPRAZOLE Tablets IP 40 mg (ENTERIC COATED)	10's			
117	485	PROMETHAZINE (FILM COATED) Tablets IP 25 mg	10's			
118	486	PANCREATIN 170 MG+ DIMETHICONE 80 MG TABLETS	10's			
119	488	LANSOPRAZOLE CAPSULES IP 15 MG	10's			
120	489	SULFASALAZINE TABLETS BP 1000 MG ENTERIC COATED	10's			
121	490	SIMETHICONE 40 MG DROPS	15 ML			
122	494	ISPAGHULA HUSK IP 100 GM	100 GM			
123	496	DYDROGESTERONE TABLETS IP 10 MG	10's			
124	498	FERROUS ASCORBATE 100MG WITH FOLIC ACID 1.5MG TABLETS	10's			
125	500	LEVO-THYROXINE SODIUM TABLETS IP 100 MCG	100's			
126	502	DEFLAZACORT Tablets 6 mg	6's			
127	505	CARBIMAZOLE TABLETS IP 10 MG	100's			
128	509	HYDROXYCHLOROQUINE Tablets IP 200 mg	10's			
129	510	PARACETAMOL 325 mg+ TRAMADOL 37.5 mg Tablets	10's			
130	511	PARACETAMOL Tablets IP 650 mg	15's			
131	521	TRAMADOL TABLETS SR 100 MG	10's			
132	523	NAPROXEN TABLETS IP 500 MG	15's			
133	524	LIDOCAINE INJECTION IP 2 %W/V	30 ml Vial			
134	529	LEVOSALBUTAMOL 1.25 MCG+ IPRATROPIUM 500 MCG RESPULES/2.5ML	2.5 ml Respules			
135	530	FORMOTERAL 6 MG+ BUDESONIDE 200 MG ROTACAP	30's			
136	532	SALMETEROL 50 MG+ FLUTICASONE 250 MG ROTACAP	30's			
137	534	SALBUTAMOL 400 MCG + BECLOMETHASONE 200 MCG RESPICAP	30's			
138	537	SALBUTAMOL 1 MG+ AMBROXOL HYDROCHLORIDE 15 MG/5 ML SYRUP	100 ml			

139	538	THEOPHYLLINE TABLETS 400 MG	10's			
140	539	ACETYLCYSTEINE Tablets 600 mg	10's			
141	540	LEVBUTEROL 1.25 MG+ BUDESONIDE 1MG REPSULE	2 ml Respules			
142	543	MENTHOL CINNAMON and PINE OIL SOFT CAPSULES	10's			
143	557	TIOTROPIUM ROTOCAP 18 MCG	15's			
144	558	FLUTICASONE 50 MCG+ AZELASTINE 140 MCG NASAL SPRAY	120 MD			
145	559	SALBUTAMOL 2MG + THEOPHYLLINE 100 MG TABLETS	30's			
146	560	FLUTICASONE PROPIONATE 50 MCG PER PUFF NASAL SPRAY	120 MD			
147	561	LEVOSALBUTAMOL 1 MG/5ML SYRUP	100 ml			
148	563	OXYMETAZOLINE 0.5 MG /ML NASAL DROPS	10 ML			
149	564	FORMOTERAL 12 MG + TIOTROPIUM 18 MG ROTOCAP	15's			
150	565	CICLESONIDE 400 MCG+ FORMOTEROL 12 MCG + TIOTROPIUM 18 MCG ROTOCAP	15's			
151	566	IPRATROPIUM 250 MCG/ML I:SOLUTION	15 ML			
152	568	SALMETEROL 50 MCG+ FLUTICASONE PROPIONATE 250 MCG /PUFF INHALER	100 MD			
153	571	Tamsulosin 0.4 mg + Dutasteride 0.5 mg Tablets	15's			
154	574	VACCINE RABIES INJECTION 2.5 IU	1 ml Amp			
155	579	Multivitamin Capsule	20's			
156	581	CALCIUM CARBONATE 500MG+CALCITRIOL 0.25 MCG + ZINC 7.5 MG Capsules	10's			
157	583	CYPROHEPTADINE Tablets IP 4 mg	10's			
158	584	CALCIUM CITRATE MALATE 250 MG , VITAMIN D3 100 IU AND FOLINIC ACID 50 MCG TABLETS	30's			
159	586	METHYLCOBALAMIN 1500 MCG, L- CARTININE L-TARTRATE 500 MG, FOLIC ACID 1.5 MG TABLETS	10's			
160	587	APPETITE ENHANCER (PEPTONE, MINERALS, VITAMINS)SYRUP	300 ML			
161	588	VITAMIN E SOFTGEL CAPSULES 400 MG	10's			
162	590	VITAMIN A, B-COMPLEX, D & E INJECTION	10 ml Vial			
163	593	NICOTINAMIDE 200 MG+ FOLIC ACID 15 MG + CYANOCOBALAMIN 0.5 MCG INJECTION	10 ml Vial			
164	594	GLUCOSE POWDER	75 gm			
165	595	THIAMINE 100 MG+ PYRIDOXINE HCl 50 MG + CYANOCOBALAMIN 1000 MCG INJECTION	2 ml Amp			
166	596	ZINC SULPHATE 20 MG/ ML ORAL SOLUTION	15 ML			
167	597	PYRIDOXINE TABLETS IP 50 MG	10's			
168	598	PREGABALIN 75 mg+ METHYLCOBALAMIN 750 MCG Tablets	10's			
169	603	Cetirizine Dihydrochloride IP 5mg, Phenylephrine HCl IP 10 mg, Paracetamol IP 325mg Tablets 10's	10's			
170	606	Cyproheptadine Tablets 4mg 10's	10's			

171	609	Silver NO3 0.20%w/w, Chlorhexidine Gluconate Soln 0.20%, Preservative Chlorocresol 0.12%w/w,Cream	15 Gm Tube			
172	616	Celecoxib 100 mg capsules	10's			
173	617	Celecoxib 200 mg capsules	10's			
174	619	Cough Paed.Syp Dextromethorphan IP5 mg+Bromhexine4mg+Phenylpropanolamine10mg+ Menthol IP 0.75mg/5ml	60 ml Bottle			
175	621	Iron & Zinc(Carbonyl Iron 50 mg+ Zinc Sulphate Monohydrate USP 61.8 mg equivalent to Elemental Zinc	15's			
176	622	Cough lozenges Ginger / Lemon (2,4Diclorobenzyl alcohol1.2 mg + Amylmetacresol 0.6 mg in flavour	8's			
177	623	Cough lozenges Regular 2,4 - Diclorobenzyl Alcohol 1.2 mg, Amylmetacresol BP 0.6 mg	8's			
178	625	Cough Tablets Bromhexine HCl 8.00 mg Phenylephrine HCl 5.00 mg	15's			
179	626	Ketoconazole Shampoo 2% W/V	100ml Bottle			
180	628	Etophylline IP 231mg. + Theophylline 69mg Tablet	10's			
181	629	Inhalent Softgel Caps(Camphor25mg+Clorothymol 5 mg+Eucalyptus130mg+Menthol 55mg+Turpentine oil110mg	10's			
182	631	Etamsylate Tablets 500 mg.	10's			
183	635	Clobetasol Proppionate BP0.05%w/wNeomycin IP0.50%w/wMiconazole IP2%w/wChlorocresol IP0.10 %w/wCream	10 gms tube			
184	637	Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone 250 mg film coated tab.	10's			
185	638	Aceclofenac 100 mg Paracetamol 325 mg Serratiopeptidase 15 mg	10's			
186	639	Mucodilator Expectorant Terbutaline Sulphate 1.25 mg Bromhexine 4 mg Guaiphenesin 50 mg Menthol 2	100 ml			
187	640	Nimesulide 1% W/W Gel	20 gm Tube			
188	643	Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a flavour syrup base	60 ML Bottles			
189	645	Nimesulide 100mg, Paracetamol 325mg, Chlorzoxazone 375mg Tablet	10's			
190	649	Dicyclomine 10mg + Act. Dimethicone 40mg per ml	10ml Bottle			
191	650	Mefenamic Acid 500mg+Paracetamol 325 mg Tablet	10's			
192	653	Syrup Vitamin D3 200 IU + Vitamin B12 2.5 mcg + Calcium Phosphate eq. to elemental Calcium 82mg /5	225ml			
193	654	Enyme Syrup Cardamom Flavour Pepsin 7.5 mg + Fungal Diastase 12.5 mg / 5 ml	200 ml			
194	656	Enzyme Drops Pepsin (1:3000) 5 mg + Fungal Diastase (1:1200) 33.33 mg/ml	15 ml			
195	658	Chlorhexidine Gluconate 0.3%v/v+Cetrimide	100 ml			

		0.6%w/v Antiseptic Liquid 100 ML				
196	660	Cetrimide 0.5% + Vit. E Acetate 0.1% + Glycerin Soap	75 gm			
197	661	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion 100ml	100 ml			
198	662	Gama Benzene Hexachloride 1 % w/v + Cetrimide 0.1% w/v lotion 200ml	200 ml			
199	674	Sitaglptin 100 mg Tablet	10's			
200	675	Sitaglptin 50 mg Tablet	10's			
201	676	Triamcinolone Acetonide 0.1 % Mouth Ulcer gel	10gm			
202	678	levodopa 250mg & Carbidopa 25mg Tablets 10's	10's			
203	679	Nalidixic Acid 500 mg Tablet	10's			
204	681	Phenazopyridine Hcl 100mg tab	10's			
205	682	Rabeprazole 20mg + Domperidone 10mg Capsule	10's			
206	693	Tropicamide Eye Drops	5 ml Vial			
207	695	Polymyxin B SO4 BP 5000 iu , Chloramphenicol IP 4mg Phenulmercuiric intrate IP Ear/Eye Drop	5 ml			
208	696	Polymyxin-B BP5000iu,Chloramphenicol IP4mg ,Dexamethasone IP 1mgPhenulmercuiric IP Ear/Eye Drop	5 ml			
209	700	Ketamine HCl 10 mg/ml Injection	20ml Vial			
210	701	Pilocar 2 % eye drop	10 ml Vial			
211	704	Cephalexin 125mg/5ml dry syrup	30 ml			
212	707	Piroxicam 10 mg tablets	10's			
213	709	Piroxicam 20 mg with bezyl alcohol injection	1ml Amp			
214	710	Piroxicam 40 mg with bezyl alcohol injection	2ml Amp			
215	716	Urea IP 1 % + Salicylic Acid IP 1% w/w Zinc SO4 0.1 % w/w cream/onit	10 gm			
216	717	Etodolac Tablets IP 300mg 10's	10's			
217	721	Water for Injection amp polypack 2ml	2ml Amp			
218	722	Water for Injection amp polypack 5 ml	5ml			
219	724	Whey Peptide based Internal nutrition ProtinFatCarbsVitADEKCBcomplexMineralCholine TaurineCarnitine	200 gm Tin			
220	732	Sodium Chloride Injection IP 0.9%w/v (Normal Saline (NS) 0.9% w/v) using FFS technology	100ml IV fluid plastic contai			
221	747	Glimepiride Tablets 3mg	10's			
222	749	Cholecalciferol-60000 iu granules	1gm sachet			
223	816	Calcium Acetate Tablets 667mg	10's			
224	817	Calcium Carbonate 1250 Mg Vitamin D3 250 Iu Magnesium Oxide 40 Mg Manganese Sulphate 1.8 Mg Zinc	10's			
225	830	Chlordiazepoxide10mg+ Trifluoperazine 1mg Tablets	10's			

226	832	Chlorthalidone Tablets 12.5mg	10's			
227	837	Cilnidipine Tablets 20mg	10's			
228	864	Dextrose Injection IP 25%w/v	100 ml			
229	884	Erythromycin Estolate Suspension 125 Mg/5ml	60ml			
230	893	Filgrastim 300mcg/1ml Prefilled Syringe	1's			
231	900	Gabapentin 100mg Methylcobalamine 500mcg Tablets	10's			
232	906	Glyceryl Trinitrate Tablets IP 2.6mg (Nitroglycerin Tablets)	30's			
233	909	Human Albumin Solution 20%	100ml vial			
234	915	Hydroxyzine HCl Tablets IP 10mg	10's			
235	931	Lamotrigine Tablets IP 100mg	10's			
236	933	Leflunomide Tablets IP 20mg	10's			
237	936	Leuprolide Acetate Injections 3.75mg	1's			
238	937	Levetiracetam Syrup100 Mg/5ml	100 ml			
239	938	Levocarnitine Injections 1gm	5ml Vial			
240	939	Levocarnitine Tablets 500mg	10's			
241	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	20 gm Tube			
242	951	Lycopene 1000 Mcg Vitamin A Palmitate 2500 Iu Vitamin E Acetate 10 Iu Selenium 35 Mcg Vitamin C	200 ml			
243	960	Metformin SR Tablets IP 850mg	10's			
244	974	Natural Micronised Progesterone Capsules 100mg	10's			
245	999	Paroxetine SR Tablet 37.5mg	10's			
246	1005	Phenobarbitone Tablets I.P 30mg	30's			
247	1041	Risperidone 4mg, Trihexiphenidyl 2mg Tab.	10's			
248	1051	Sertraline Tablets I.P 25mg	10's			
249	1059	Sodium Valproate EC Tablets I.P 200mg	10's			
250	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	10ml			
251	1098	Voglibose 0.2mg, Metformin 500mg SR Tablets	10's			
252	1123	Clomipramine Hydrochloride SR Tablets 75mg	10's			
253	1125	Aripiprazole Tablets 5mg	10's			
254	1129	Teneligliptin 20mg + Metformin 500mg Tablet SR	10's			
255	1149	Lisinopril 10mg Tabs	15's			
256	1156	METOPROLOL 25 MG + AMLODIPINE 5 MG TABLETS	7's			
257	1164	NANDROLONE DECANOATE INJECTION IP 50 mg/ml	2 ml Amp			
258	1178	5-Flurouracil Inj. 500mg	10 ml Vial			
259	1181	Carboplatin Injection 150mg	15 ML Vial			
260	1210	Bendamustine 100 mg Injection	VIAL			
261	1213	Erlotinib 150 mg Tablet	10's Bottle			
262	1214	Gefitinib 250 mg Tablets	10's			
263	1215	Pemetrexed 100 mg Injection	VIAL			
264	1216	Pemetrexed 500 mg Injection	VIAL			
265	1224	Povidone-Iodine 10% antiseptic paint	50 ml			

266	1229	Levosalbutamol+Ipratropium(2.5+500)mcg Respules	2.5 ml Respules			
267	1232	Noscapine 1.83mg/5ml Syp	50 ml			
268	1237	Methyldopa tabs 500mg	10's			
269	1238	Prazosin Tablets 2.5mg "SR" Tab	30's			
270	1239	GLIMEPIRIDE 2 mg + METFORMIN HYDROCHLORIDE 500 mg SR Tablets,15's	15's			
271	1241	Cefaclor Tablet I.P 250 mg tabs	10's			
272	1242	Cefaclor Tablet I.P 375 mg tabs	10's			
273	1243	Betamethasone 0.05% w/w + Salicylic acid 3% w/w cream	20 gm Tube			

ANNEXURE-IX

Ref: Clause No. 9.5

Letter of acceptance of tender for price agreement

Speed post/e-mail

Ref. No. BPPI/ Drug – 065/2018 **Date: ……..**

To,
M/S ----------

Sub: Tender for the Supply of Drugs and Medicines to BPPI for the years 2018-2019: Acceptance tender for price agreement and Deposit of Performance Security Amount.
Ref: Your quotation against BPPI e-Tender No. BPPI/DRUG-065/2018 dated: 03/08/2018 opened on ……. (Technical Bid) & on ……(Price bid).

Please refer to your quotation i.e. technical and price bid (BOQ) along with enclosures/Annexure against subject tender read with your subsequent clarification/confirmation for the supply of Drugs to BPPI for the years 2018-2019, the rate offered/accepted by your firm has been approved for price agreement for one year i.e. up to …….as per details below: -

S. N.	Drug Code	Drug Name	Unit Size	Quantity	Rates in Rs. Per unit exclusive of GST	Rate of GST	Rates in Rs. Per unit inclusive of GST	Rs.(including GST)
Total value of price agreement								

2.You are requested to kindly remit performance security deposit in form of demand draft or irrevocable bank guarantee from scheduled bank which is equivalent to Rs as stipulated in the tender document within 15 days from the date of receipt of this letter for the supply of **Drugs to BPPI**. Format for Bank Guarantee towards performance security deposit shall be as per Annexure X of tender document.
Performance security deposit if paid in form of Bank Guarantee should be valid for two years from the date of issue i.e. Valid till ……/2020.

3. Approval for Artwork should to be obtained from our Quality Control department by you within 30 days of release of this letter. (e-mail id: regulatory@janaushadhi.gov.in)

4.The terms and conditions of price agreement shall be applicable as mentioned in tender document. By issue of this acceptance letter, the price agreement is hereby concluded.

5. As per clause 8.6 of Tender document, the Price agreement validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.

Please acknowledge receipt.

BPPI

ANNEXURE -X

Ref. Clause No.10.1

Performance Security Bank Guarantee

(unconditional)

To: Bureau of Pharma Public Sector Undertakings of India, (Name of purchaser) 8th Floor, Videocon Tower, Block-E1,Jhandewalan Extension, New Delhi-110055

WHEREAS……(Name of the Supplier) herein called "the Supplier" has undertaken, in pursuance of Tender **BPPI/DRUG-065/2018 Dtd. 03/08/2018** to supply of **Drugs for the year 2018-2019,** (Description of Goods and Services) hereinafter called "the Contract".

AND WHEREAS it has been stipulated by you in the said Contract that the Supplier shall furnish you with a Bank Guarantee for the sum specified therein as security for compliance with the Supplier's performance obligations in accordance with the Contract.

AND WHEREAS we have agreed to give the Supplier a Guarantee

THEREFORE WE hereby affirm that we are Guarantors and responsible to you, on behalf of the Supplier, up to a total of …….(Amount of the Guarantee in Words and Figures) and we undertake to pay you, upon your first written demand declaring the Supplier to be in default under the Contract and without cavil or argument., any sum or sums within the limit of ……..(Amount of the Guarantee in Words and Figures) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

This guarantee is valid until the …….day of……2021.

Signature and Seal of Guarantors

……
……
……

Date…….

Address……

……

ANNEXURE -X1

Ref. Clause no 13

DECLARATION

I/We do hereby declare that I/we will supply the drug as per the design in enclosures to this Annexure as well as other instruction given in this regard.

Signature of the Tenderer

Name

Designation

(Company Seal)

ANNEXURE – X1 (A)

Ref. Clause No. 13

UNDERTAKING

I / we do hereby declare that I/we will supply the drugs by affixing logo on Primary/Secondary/ Tertiary packing for the imported items along with the generic name as per the designs given in enclosures to this annexure as well as other instructions given in this regard.

Signature of the Tenderer

(Name in capital letter with designation)

Enclosure–1 to ANNEXURE - X1 AND X1 (A)

Ref. Clause No. 13

DESIGN FOR: Foil / blister of tablet and capsule

1. **Text Matter Printing on** Foil /Blister should be in minimum two colour i.e. Black & red. **However, colour and design of PMBJP(Pradhan Mantri Bhartiya Janaushadhi Pariyojana) logogram in standard colour format & BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply should be as given below.**

2. PMBJP Logogram should be placed along with the address as given below.
3. BPPI helpline number 1800 180 8080 should be printed.

4. Font type should in CALIBIRI format for any type of title name of generic medicines.

5. Title name of generic medicine should be **bold** in minimum 12 font size & the strength corresponding to it must be **bold** in minimum 14 font size and it may increase respectively according to size of label & the rest text matter should be in minimum 8 font size.
6. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.

7. "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

1. Pradhan Mantri Bharitya Janaushadhi Priyojana should be printed in Hindi at side of strips.

Enclosure – 2 to ANNEXURE – X1 &ANNEXURE – X1 (A)

Ref. Clause No. 13

1. **Design for injection for primary packing**

a) Vial (5ml or more) should be supplied with the following PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as under:

b) BPPI helpline number 1800 180 8080 should be printed

c) Font type should in CALIBIRI format for any type of title name of generic medicines

d) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for : Bureau of Pharma PSUs of India 8th Floor, Videocon Tower, Block-E1,Jhandewalan Extension, New Delhi-110055 BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

b) Ampoules or Vials less than 5 ml for primary packing

(i) Injection in ampoule or vial (less than 5 ml) should be supplied with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply**.

(ii) BPPI helpline number 1800 180 8080 should be printed.

(iii) Font type should in CALIBIRI format for any type of title name of generic medicines.

(iv) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.

(v) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for :

Bureau of Pharma PSUs of India

8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055

BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

(ii) LIQUID:

a) Liquid preparation should by supply with pilfer proof ROPP cap.

b) Bottle cap should not bear the manufacturer's logogram

c) Bottle label should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as below:

d) BPPI helpline number 1800 180 8080 should be printed

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

f) Font type should in CALIBIRI format for any type of title name of generic medicines

g) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.

Manufactured for :

Bureau of Pharma PSUs of India

8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055

BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

3. OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as below:

Manufactured for :

प्रधानमंत्री भारतीय जन औषधि परियोजना

Bureau of Pharma PSUs of India

8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055

BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

b) BPPI helpline number 1800 180 8080 should be printed

c) Ointment / cream tube should be packed in mono carton (secondary packing) with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as given below.

d) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

e) Font type should in CALIBIRI format for any type of title name of generic medicines

f) Title name of generic medicine should be minimum 12 font size and it may increase respectively according to size of label.

Enclosure 3 to ANNEXURE – X1 (A)

SPECIMEN LABEL FOR MONO CARTON (Secondary Packing)

Rx 10 X 10's Tablets

Generic Name of Product

प्रधानमंत्री भारतीय जन औषधि परियोजना

Manufactured for :
Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

For Ampoules/vials :- All secondary packing box/carton should be supplied with printed text matter as per guidelines.

Note: Any additional statuary requirement under Drug & Cosmetic Act 1940 and rules 1945 shall be printed.

ANNEXURE-XII

Ref. Clause No.14.1

SCHEDULE FOR PACKAGING OF DRUGS

GENERAL SPECIFICATIONS

1. Strips of Aluminium foils should be 0.04 mm thickness.
2. Aluminium foils s back material for blisters should be minimum 0.025 mm thickness.
3. The rigid PVC used in blister packing should be of not less than 250 micron
4. All glass bottles should be new neutral glass. Pet bottles so accepted as per drug laws stipulation.
5. Ointments should be packed in lacquer zed Aluminium Tubes or Lami tubes.
6. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
7. Specification of outer cartons are as given in this Schedule.
8. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
9. All plastic containers should be made of virgin grade plastics
10. Injection in vials should have a flip-off seals.
11. The strips shall be aluminium strip / blisters with aluminium foil back.
12. The minimum diameters of each tablets should be of 6.4mm
13. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**)**. The material to be used for carton should be from virgin chemical pulp.**
14. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle in a mono carton. In case of Paediatric Preparation, all liquid oral has to be provided with a measuring plastic cup, dropper fitted over the cap of the bottle in a mono carton.

15. All primary/secondary/tertiary packaging should have PMBJP logo and BPPI DRUG CODE—XXXX as per PO..

16. Two Horizontal/vertical/standing lines in two different colour will be there on Primary and secondary packaging, so as to differentiate therapy groups. The colours of lines will be intimated during Artwork approval.

17. The primary packing should be decided by the party depending on the drug category as per D&C act. For e.g if drug is hygroscopic then tablet should be packed in Alu/Alu blister or if it is light sensitive then to be packed in Amber colour PVC e.t.c.

(Schedule)

1.	**CORRUGATED BOXES(Liquid)**
	1. No corrugate package should weigh more than 15 kgs (i.e. product + inner carton + corrugated box). 2. All Corrugated boxes should be of `A' grade paper i.e. Virgin and 7 Ply. 3. All items should be packed only in first hand boxes only.
2.	**FLUTE**
	The corrugated boxes should be of narrow flute.
3.	**JOINT**
	Every box should be preferably single joint and not more than two joints.
4.	**STITCHING**
	Every box should be stitched using pairs of metal pins with an interval of two inches between each pair. The boxes should be stitched and not joined using calico at the corners.
5.	**FLAP**
	The flaps should uniformly meet but should not over lap each other. The flap when turned by 45 – 60 degree should not crack.
6.	**TAPE**
	Every box should be sealed with gum tape running along the top and lower opening.
7.	**CARRYSTRAP:** Every box should be strapped with two parallel nylon carry straps (they should intersect).
8.	**LABEL**
	The product label on the carton should be large at least 15 cms x 10 cms dimension. It should carry the correct technical name, strength of the product, date of manufacturing, date of expiry, quantity packed and net weight of the box.
9.	**OTHERS**
	No box should contain mixed products or mixed batches of the same product.

II. SPECIFICATION OF CORRUGATED BOXES HOLDING TABLETS / CAPSULES / PESSARIES

(1) The box should not weigh more than 7-8 kgs. The grammage of outer box should be 150 gsm and inside partition / lining should be 120 gsm.

(2) The box should be of 7 ply with bursting strength of 9 Kg / Cm2

III. SPECIFICATIONS OF CORRUGATED BOXES FOR OINTMENT / CREAM / GELS PACKED IN TUBES:

(1) No corrugate box should weigh more than 7-8 Kgs.

(2) Every Ointment tube should be individually packed in carton and then packed in 20's in a white board box, which may be packed in a corrugated box.

(3) Grammage: Outer box should be 150 gsm inside partition /

Lining should be 120gsm.

IV. SPECIFICATIONS OF CORRUGATED BOXESFOR INJECTABLE (IN VIALS AND AMPOULES)

(1) Vials may be packed in corrugated boxes weighing up to 15 Kgs. Ampoules should be packed in C.B weighing not more than 8 kgs.

(2) C.B. for vials should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply, while C.B. for ampoules should be of 150 gsm (outer box should be 150 gsm and inside partition / lining should be 120 gsm) and 7 ply.

(3) Bursting strength for CB boxes for

i. Vials : Note less than 13 Kg/Cm2

ii. Amp : Note less than 9 Kg/Cm2

(4) In the case of 10 ml Ampoules, 20 or 25 ampoules may be packed in a mono carton. Multiples of mono carton boxes should be packed in CB.

(5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with centre pad.

(6) In case of ampoules less than 10 ml, every 10 or 5 ampules should be inside the tray with printed white board box.

(7) Vials of eye, ear drops and nasal drops should be packed in an individual mono carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed in 50's in a white board box.

ANNEXURE -XIII

MANDATE FORM

Ref. clause 16.2

Sl.No.	Details Required		
1.	**Company Name**		
	PAN Number		
	TIN Number		
	GST NO.		
	Date of Inception		
	Licence No. & Date		
	Issued By		
	Valid Upto		
2.	Postal Address of the Company		
	Telephone No.		
	Fax No.		
	E-mail ID		
	Alternate E-mail ID		
3.	**Name of the Managing Director / Director / Manager**		
	Mobile No. / Phone No		
	E-mail ID		
4.	Name and Designation of the authorized company official	Name:	
		Designation:	
	Mobile No.		
	E-mail ID		
5.	**Bank Details**		
	a) Name of the Bank		
	b) Branch Name & address		
	c) Branch Code No.		
	d) Branch Manager Mobile No.		
	e) Branch Telephone no		
	f) Branch E-mail ID		
	g) 9 digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank		
	h) IFSC Code of the		

	Branch		
	i) Type of Account (Current / Savings)		
	j) Account Number (as appear in cheque book)		

(In lieu of the bank certificate to be obtained, please **upload the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / Price agreement and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Company Seal Signature

Place: (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:
